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N-Thiolated β-Lactam Antibiotics: Synthesis and Structure-Activity Studies 
of C3-Oxygenated Derivatives and Attachment to New, Functionalized 
Caprolactone Monomers and Polymers 
 
J. Michelle Leslie 
 
 
ABSTRACT 
 
 
N-Thiolated β-lactams are a new class of anti-MRSA and anti-Bacillus 
agents that have recently been reported by our laboratories. From previous 
studies performed in our laboratories, it is believed that the N-thiolated β-lactams 
exert their antimicrobial activity through a unique mode of action that is 
completely unlike that of classical β-lactam antibiotics. In the first chapter of this 
dissertation, a review of previously prepared N-thiolated β-lactam analogues and 
their mode of action is presented. In the second chapter, the synthesis of seven 
different C3-oxygenated derivatives is described. These analogues were tested 
for antibacterial activity against Staphylococcus aureus, nine different strains of 
MRSA, and seven different species of Bacillus. The results of the antibacterial 
testing will be discussed in relation to the differences in the structures of the 
analogues. In chapter 3, the design and synthesis of two new, functionalized 
caprolactone monomers are presented. These monomers were subsequently 
cooligomerized with ε-caprolactone, as described in chapter 4. N-thiolated β-
 xv
lactams were attached to the functionalized oligomers. These antibiotic 
containing oligomers were then screened for activity against MSSA, MRSA, and 
Bacillus. The results of these biological tests and their implications for future 
experiments are discussed. 
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Chapter 1 
Introduction to the N-Thiolated β-Lactam Antibiotics 
 
1.1 Penicillin and other β-lactam antibiotics 
 
For over 60 years, the penicillins (and other β-lactam antibiotics) have 
been broadly used for the treatment and prevention of bacterial infections.1 
Following the commercial availability of penicillin in 1940, many other β−lactam 
antibiotics were also prepared and tested.2 The general structures of the most 
common families of β-lactam antibiotics are shown in Figure 1.1.  The key 
structural features of penicillin and its analogues such as the penams (2), 
penems (3), carbapenems (4), cephalosporins (5), clavulanic acids (6), 
nocardicins (7) and monobactams (8) are the β-lactam ring, and an ionizable ring 
functionality. The nocardicins, 7, discovered in 19763, were the first monocyclic β-
lactams that exhibited high antibacterial activity.4 The monobactams, 8, were the 
first β-lactam analogues to have a sulfur atom attached directly to the lactam 
nitrogen.5  
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Figure 1.1 β-lactam family of antibiotics 
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1.1.1 Mode of action of the β-lactam antibiotics 
 
All of the β-lactam antibiotics that are shown in Figure 1.1 are water 
soluble in their salts forms, and attack the bacteria from the outside (without 
entering the cell).1 These antibiotics kill bacteria by targeting the membrane-
bound transpeptidases which are responsible for creating cross-links within the 
cell wall of the bacteria.2 These crosslinks are formed  by the transpeptidases 
through the replacement of a terminal D-alanine residue on one peptidoglycan 
strand with the glycine residue from a neighbouring peptidoglycan chain. The 
 3
cleavage of the D-alanine residue happens when an active site serine adds to 
the amide functionality in a nucleophilic fashion producing an enzyme-linked 
peptidoglycan (Scheme1.1). This enzyme-linked peptidoglycan then undergoes 
an amidation reaction, which releases the serine for further catalysis.  
 
Scheme 1.1 Formation of cross-links in bacterial cell wall 
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Penicillin and related β-lactams irreversibly block this process by acylating 
the serine hydroxyl group (Scheme 1.2). The ionizable ring functionality in these 
drug molecules is required for binding to the enzyme. The resulting enzyme drug-
adduct is stable and catalytically inactive. The disruption of these cross-linking 
proteins leads to structural deformities within the cell wall which make the 
bacteria prone to rupture, which leads to the death of the bacterium. 
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Scheme 1.2 Acylation of active site serine by penicillin 
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1.1.2 Resistance problems 
 
 
 Penicillin and the β-lactam antibiotics were considered to be “wonder 
drugs”, and with their discovery, many thought that the war on infectious disease 
was over. Unfortunately, penicillin-resistant strains of bacteria began to emerge 
soon after its introduction.7 The resistant bacteria fought back against the β-
lactam antibiotics by developing enzymes (β-lactamases) which could hydrolyze 
the β-lactam ring, thereby rendering the antibiotic inactive. The advent of 
resistant bacteria makes the ongoing research to develop new classes of 
antibiotics essential.  
 
1.2 Non-conventionally fused β-lactams 
 
In 1994, Ren et al. first reported the synthesis of non-conventionally fused 
β-lactams.8 In this study, new β-lactam antibiotics where the β-lactam ring was 
reorganized so that the lactam nitrogen was directly attached to a sulfur atom 
were prepared (Figure 1.2). These derivatives were called N-thiolated bicyclic β-
lactams and it was hoped that these analogues might provide useful leads in the 
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search for new antibiotics. Compounds 9 and 10 are penem-monobactam 
hybrids, and compounds 11 and 12 are clavulanic acid-monobactam hybrids.  
 
 
Figure 1.2 N-thiolated bicyclic β-lactams 
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 These new hybrids were screened for antibacterial activities against a 
wide variety of common strains of Gram-positive and Gram-negative bacteria. 
However, none of these new bicyclic compounds showed any appreciable 
antimicrobial effects. In the preparation of these bicyclic compounds, Ren 
developed a protocol involving an iodocyclization reaction of an unsaturated 
compound (13) (Scheme 1.3).9 
 
Scheme 1.3 Iodocyclization reaction 
N
O S CH3
H3CO
Ph
N S
H3CO I
Ph
O
H H
N S
H3CO I
Ph
O
H H
O O
mCPBA
CH2Cl2
82%
I2, CH2Cl2
40oC, 80%
(13) (9) (10)  
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The intermediate, 13, was also screened for antibacterial activity against 
the same panel of common bacteria, and it was found to be a powerful growth 
inhibitor of Staphylococcus aureus, including the multi-drug resistant 
Staphylococcus aureus (MRSA).10 With this discovery, a large structure-activity 
relationship (SAR) study was undertaken in the Turos laboratory to study these 
new monocyclic N-thiolated β-lactams in more detail.  
 
1.3 Analogues of N-thiolated β-lactams 
1.3.1 First N-thiolated monocyclic β-lactams analogues 
 
Compounds that were structurally similar to 13, varying only in the spacer 
unit between the β-lactam ring and the aryl substituent at the C4 position, were 
prepared first.11 Compounds where there was no spacer unit (18 and 19) were 
selected for further study because their bioactivities were comparable to that of 
the C4- acetylenic lead compound, 13, and also because they were easily 
prepared. 
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Figure 1.3 N-thiolated monocyclic β-lactams 
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1.3.2 C4 Aryl analogues  
Numerous analogues of 18 where the position and nature of the 
substituents on the C4 aryl ring was varied were prepared (Figure 1.4).11,12 
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Figure 1.4 C4 Aryl derivatives of N-thiolated β-lactams 
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Some examples of the C4 aryl analogues that were studied include: 
monohalogenated compounds 20, 21, 22, 23, 24, 25, 26,and 27; dichlorinated 
compounds 28 and 29; trichlorinated analogue 30; nitrated derivatives 33 and 34; 
and compounds that contain electron-donating substituents such as 31, 32, 35, 
36, 37, 38, and 39. 
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1.3.3 N-organothio analogues 
 
 The effect of the substituent on the sulfur atom was also studied by Bart 
Heldreth in our laboratory.13 The length of the substituent chain, degree of 
branching, and oxidation state of the sulfur was studied. Examples of some of the 
N-organothio analogues that were prepared are shown in Figure 1.5. These 
analogues include: straight chain sulfenyl compounds 40, 41, 42 and 43; 
branched sulfenyl compounds 44, 45, 46 and 47; aryl sulfenyl compounds 48 and 
49; sulfinyl compounds 50 and 53; sulfonyl compounds 51 and 54; and sulfonic 
acid 52. 
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Figure 1.5 N-Organothio derivatives of N-thiolated β-lactams 
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1.3.4 C3 monosubstituted β-lactams 
 
 
It had been previously determined that compounds that were either 
unsubstituted14 or had a simple alkyl substituent15 at the C3 position were either 
completely inactive against MRSA, or only weakly active. The compounds that 
had showed the strongest bioactivity had a methoxy substituent at this position. 
This suggested that a polar group at the C3 position is required for bioactivity. To 
determine how other substituents at this position affect the bioactivity, a wide 
variety of compounds that were monosubstituted at the C3 position were 
prepared.12 These compounds vary in their polarities, lipophilicities, size (steric 
bulk), hydrogen bonding capabilities and stereochemistry. Examples of some of 
the C3 monosubstituted β-lactams that were prepared are shown in Figure 1.6. 
The functional groups incorporated at this position include: azide 55; halides 56 
and 57; amines 58, 59, 60, and 61; ether 62; ester 63; and sulfonates 64, 65, and 
66.12 
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Figure 1.6 C3 Monosubstituted derivatives of N-thiolated β-lactams 
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1.3.5 C3 disubstituted β-lactams 
 
 Compounds that were disubstituted at the C3 position were also prepared 
to continue investigating the role of the C3 substituent and to study the effect of 
increased steric crowding at this center (Figure 1.7). Compounds 67, 68 and 69 
have both an alkyl group and an ester group at C3. Compounds 70, 71, and 72 
contain spirocyclic ethers at the C3 position. 
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Figure 1.7 C3 Disubstituted derivatives of N-thiolated β-lactams 
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1.4 Mode of action of the N-thiolated β-lactam antibacterials 
 
 The initial screening of the N-thiolated β-lactams against a variety of 
common strains of Gram-positive and Gram-negative bacteria showed that these 
compounds exhibited narrow spectrum bioactivity. These lactams showed activity 
against members of the Staphylococcus genus including S. aureus (and MRSA), 
S. epidermidis, S. simulans, S. saprophytcus; and a few other genera such such 
as Micrococcus luteus and Neisseria gonorrhoeae.11 A wide variety of other 
Gram-negative and Gram-positive bacteria seem to be unaffected by these 
lactams. The discovery that these β-lactams have any antibacterial activity at all 
was surprising at first, given that they lack an ionizable ring functionality (required 
by all other known β-lactams for binding to the bacterial transpeptidase). 
 Studies done by Dr. Timothy Long in our laboratory showed that the N-
thiolated β-lactams do not inhibit cell wall biosynthesis. Bacterial cells that had 
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been treated with an N-thiolated β-lactam were examined by scanning electron 
microscopy (SEM) and it was observed that there was no change to the cellular 
morphology. When bacterial cells that had been treated with penicillin were 
viewed using SEM, drastic alterations in the cell morphology were observed. 
Gram staining of cells treated with either an N-thiolated β-lactam or penicillin 
showed that there was no change in the thickness of the cell wall for those cells 
treated with the N-thiolated β-lactam (staining purple), while the cell walls were 
significantly thinner (and stained pink) when treated with penicillin. These 
observations showed that the N-thiolated β-lactams had a mode of action that 
was different than classical β-lactam antibiotics.  
 Additional studies showed that the N-thiolated β-lactams were stable to 
acidic conditions, mildly basic conditions and radicals. However, it was found that 
these lactams were not stable to thiols such as glutathione. In the presence of 
thiols, such as 2-mercaptopyridine, a nucleophilic attack at the sulfur atom by the 
thiol is observed to form the mixed disulfide (Scheme 1.4). 17 
 
Scheme 1.4 Reaction of N-thiolated β-lactam with 2-mercaptopyridine 
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It was found that the N-thio substituent (SR) was required for bioactivity11 and 
that the addition of thiols, like glutathione, to the lactams reduced their 
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bioactivity.16,17 These observations led to the hypothesis that the bioactivity of 
these N-thiolated β-lactams is due to the transfer of the N-organothio group to a 
thiol target in the cell. It was later found that these lactams transfer the thiol 
group to Coenzyme A (CoA) to form the mixed CoA disulfide (scheme 1.5).17  
 
Scheme 1.5 Transfer of N-organothio substituent to Coenzyme A 
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 Later studies in our laboratory by Dr. Kevin Revell have shown that these 
mixed CoA disulfides inhibit fatty acid biosynthesis by capping FabH, a key 
enzyme in type II fatty acid synthesis. Inhibiting fatty acid biosynthesis stops the 
growth of the bacterium.18 
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1.5 Conclusions 
 
 A new class of monocyclic β-lactam antibiotics, called the N-thiolated β-
lactams, has been discovered by our laboratories. These lactams exhibit narrow 
spectrum antibacterial properties and are particularly effective against 
Staphylococcus aureus, including MRSA.  Previous work by Tim Long in our 
laboratory has shown that these new antibiotics do not act on the bacteria in the 
same way as the previously known classes of β-lactams. Later work by Bart 
Heldreth and Kevin Revell in our lab has shown that the N-thiolated β-lactams 
enter the bacterial cell and transfer the alkylthio group to coenzyme A to form the 
mixed CoA disulfide. These mixed CoA disulfides stop the growth of the 
bacterium by inhibiting FabH, a key enzyme in type II fatty acid synthesis. 
 A large SAR study was undertaken by our group in order to better 
understand how each of the ring substituents contributes to the observed 
antibacterial properties. The results of the biological screening of the analogues 
shown in this chapter, as well as some new C3 hydroxy and alkoxy analogues, 
will be discussed in chapter 2.  
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Chapter 2 
 Results of the SAR Studies of N-Thiolated β-Lactams and the Synthesis of 
C3 Hydroxy and Alkoxy analogues. 
 
2.1 Introduction  
 
 This chapter will focus on the results of SAR studies done in the Truos 
laboratory for the N-thiolated β-lactam antibiotics. The results of the biological 
screening of the analogues described in Chapter one, as well as seven new C3 
oxygenated analogues 73-79 (Figure 2.1), will be discussed. The synthesis of 
these seven new analogues will also be described.  
 
Figure 2.1 C3-oxygenated β-lactam analogues. 
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2.2 Results and Discussion 
 
2.2.1 Synthesis of the C3 secondary hydroxy and alkoxy derivatives 
 
The β-lactam derivatives shown in Figure 2.1 were derived from a 
common intermediate, the C3 acetoxy β-lactam 84. This intermediate was easily 
prepared as a racemate in two steps as shown in Scheme 2.1. 
 
Scheme 2.1 Synthesis of C3-acetoxy β-lactam 84 
N
O
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O
O Cl
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O
N
OCH3
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83
82
84
b
 Reagents and conditions: (a) neat, 5min; (b) 1.8 eq. 83, 3 eq. Et3N, dry CH2Cl2,
12h, 0 oC-rt; (c) KOH, acetone/MeOH, 5min, 0 oC.
OCH3
NH2
CHO
Cl+
a
80 81
 
 
Upon mixing together p-anisidine (80) and o-chlorobenzaldehyde (81) at 
 21
room temperature, imine 82 formed as a yellow paste within minutes. The paste 
was then crystallized from methanol to give pure 82 as bright yellow crystals in 
nearly quantitative yield. The imine was combined with acid chloride 83 
(commercially available or readily prepared in two steps from glycolic acid1) using 
a typical Staudinger coupling2 to give the β-lactam 84 as a white solid with typical 
yields of 80-90%. The β-lactam (84) was obtained as a racemic mixture of the 
cis-isomers, whose stereochemistry was assigned based on the vicinal coupling 
constant (J = 5.0 Hz) for the protons at the C3 and C4 positions of the ring3. All of 
the compounds presented in this chapter are racemic; any stereochemistry that 
is indicated in the schemes indicates relative stereochemistry, not absolute 
stereochemistry. 
 The C3 alcohol derivative 73 was prepared in three steps from 84, as 
shown in Scheme 2.2. The order of protection/deprotection steps was completed 
as shown to avoid the intermediate that contained both an alcohol and a free 
amide due to the solubility problems associated with this compound. The 
synthesis of β-lactam 73 began with the oxidative cleavage of the amide 
protecting group (p-methoxyphenyl, or PMP) with ceric ammonium nitrate4 (CAN) 
to give the free amide 85 in modest yields of 60-70%. The free amide was 
thiolated using N-methylthiophthalimide5 (86) and a catalytic amount of a tertiary 
amine base to give 63 as a yellow solid in 70% yield. The hydrolysis of the 
acetate substituent was accomplished very rapidly with one equivalent of 
potassium carbonate in methanol to give 73 as a pale yellow solid in 74% yield.  
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Scheme 2.2 Synthesis of C3 hydroxy β-lactam (73). 
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The synthesis of the C3 secondary alkoxy derivatives 74-76 also began 
with lactam 84 (Scheme 2.3). The syntheses of these three C3 secondary alkoxy 
derivatives began with the hydrolysis of the acetate group of 84 to give the 
alcohol 87.  This hydrolysis reaction occurs rapidly with potassium hydroxide to 
give 87 as a white solid in nearly quantitative yields. The C3 alkoxy groups were 
installed via a Williamson ether synthesis using either methoxymethyl (MOM) 
chloride or allyl bromide and alcohol 87 in the presence of a catalytic amount of 
tetra-butylammonium iodide (TBAI). The PMP protecting group was then cleaved 
using CAN. Allyl ether 90 was subjected to catalytic hydrogenation to afford the 
propyl ether 91 in quantitative yield. All of the compounds were then N-thiolated 
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with methylthio-transfer reagent 86 in the same manner as described before to 
give 74-76 in 25, 40, and 35% yield respectively, following column 
chromatography. The low final yields on these reactions are due to the difficulty 
in separating the final products from residual reagent 86.  
 
Scheme 2.3 Synthesis of the C3 secondary alkoxy β-lactams 74, 75 and 76. 
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 The C3 tertiary ether derivatives were then prepared to explore the effect 
of steric crowding at this center on bioactivity. All of these compounds were 
made from the tertiary alcohol 94, whose synthesis is shown in Scheme 2.4. 
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Scheme 2.4 Synthesis of tertiary alcohol 94 from 87. 
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Reagents and conditions: (a) P2O5, DMSO, 12h, rt; (b) MeMgI, dry Et2O,
4h, -78 oC.  
 
 Alcohol 87 was subjected to oxidation under Moffatt-Swern conditions6 to 
give the C3-keto-β-lactam compound 93 as a light yellow solid in yields of 90-
95%. Methylmagnesium iodide (generated in situ from MeI and Mgo) was then 
added to 93 in anhydrous diethyl ether to give the tertiary alcohol 94 as a yellow 
solid in 70-75% yield. The methyl group was added exclusively to the face anti to 
the C4 aryl substituent, consistent with previously reported data for a similar 
system by Buynak7, and also determined in our laboratory by Dr. Cristina Coates 
(for a related compound) using ROESY-NMR6.  The stereochemistry indicated for 
compounds 87 and 94 in Scheme 2.4 is relative, not absolute. 
 The synthesis of the C3 tertiary alkoxy derivatives 77, 78, and 79 was 
accomplished following an analogous procedure to that used for the C3 
secondary alkoxy derivatives (Scheme 2.5). 
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Scheme 2.5 Synthesis of the C3 tertiary alkoxy β-lactams 77, 78, and 79. 
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The synthesis of these three tertiary ether derivatives began with alcohol 
94 being treated under Williamson ether synthesis conditions using either MOM 
chloride or allyl bromide in the presence of a catalytic amount of TBAI. The yields 
of these reactions were slightly lower than the analogous reactions with the 
secondary alcohol, presumably due to steric crowding at the hydroxy center. The 
PMP protecting group was then cleaved with CAN to give the free amide 
compounds 97 and 99 in 74 and 95 % yield respectively, after column 
chromatography. Allyl ether 97 was subjected to catalytic hydrogenation to afford 
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the propyl ether 98 in quantitative yield. All of the compounds were then N-
thiolated using N-methylthiophthalimide (86) as described before.  
 
2.2.2 MRSA and Bacillus 
 
The N-thiolated β-lactams were individually screened for antibacterial 
activity against nine different strains of multi-drug resistant Staphylococcus 
aureus (MRSA) and also against seven species of Bacillus: Bacillus anthracis, 
Bacillus globigii, Bacillus thuringenis, Bacillus megaterium, Bacillus coagulans, 
Bacillus subtilis and Bacillus cereus. MRSA was selected for screening because 
it is the resistant form of Staphylococcus aureus, the microbe against which the 
N-thiolated β-lactams had previously shown potent growth inhibition.8 For the 
MRSA screening, penicillin G and vancomycin (current therapeutic for MRSA) 
were also screened as a reference. Since Staphylococcus and Bacillus are both 
members of the same order (Bacillales) of bacteria, the N-thiolated β-lactams 
were also screened for anti-Bacillus activity.9 Recent concerns about the possible 
use of anthrax (causative agent = Bacillus anthracis) as a biological weapon has 
led to increased interest in the development of new anti-anthrax agents. For the 
Bacillus screening, the current anti-Bacillus treatment, ciprofloxacin, was used as 
a reference. 
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2.2.3 Kirby-Bauer assay 
 
The β-lactams that were prepared in this study were individually screened 
for antimicrobial activity using the Kirby-Bauer method10 of disc or well diffusion 
(Figure 2.2).  
 
Figure 2.2 The Kirby-Bauer test for antibiotic susceptibility 
Bacterial Growth
Cellulose Disc
or Well
Zone of Growth 
    Inhibition
 
 
In this assay, the test organism is first inoculated onto Mueller-Hinton 
agar. Then 20 μg of the drug was placed onto the agar plate, either on a 6 mm 
cellulose disc or as a 1mg/mL solution in DMSO that was placed into 6 mm 
circular holes cut into the agar. The plates were incubated at 37 oC for 24 hours 
and then the zones of growth inhibition around the disc or well were measured. It 
has been demonstrated previously in our laboratory that the Kirby-Bauer test 
results correlate well with the minimum inhibitory concentration (MIC) values that 
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were obtained from broth dilution experiments, and therefore is a reliable way to 
measure bioactivity within a closely related series of analogues11.  
 
2.2.4 Results of biological screening against MRSA 
The results of the anti-MRSA studies on the C4 aryl analogues that were 
presented in Chapter 1 (Figure 1.4) are shown in Table 2.1. Also included in 
Table 2.1 are the zones of growth inhibition for the two reference drugs, Penicillin 
G and Vancomycin.11 Compounds 19, 20, and 21 are the ortho, meta, and para 
monochlorinated compounds. Compounds 22, 23, and 24 are the ortho, meta, 
and para monofluorinated compounds. Compounds 25, 26, and 27 are the ortho, 
meta, and para monoiodinated compounds. For all of these compounds, the 
activity is independent on which halogen is present on the ring, but is dependent 
on the position of the substitution. The compounds possessing ortho substituents 
displayed the greatest anti-MRSA activity, followed by those with para 
substituents and then those with meta substituents. Compounds which contained 
more than one halogen substituent on the C4 aryl ring such as dichlorinated 
lactams 28 and 29, and trichlorinated analogue 30 were also screened for anti-
MRSA activity. The zones of inhibition for these polychlorinated compounds were 
slightly lower than those of the monochlorinated compounds 28, 29 and 30 (17-
24 mm, 16-21 mm and 18-24 mm, respectively). Nitro substituted compounds 33 
and 34 both had lower bioactivities than the monohalogenated compounds 19-
27. Again, as was the case with the halogens, the ortho substituted analogue 33 
had greater zones of inhibition than the meta substituted analogue (18-23 mm for 
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33 and 11-22 mm for 34).  The effect of having electron-donating groups on the 
C4 aryl ring was also studied. Compounds 31 and 32 which contained small 
electron-donating groups at the ortho position showed bioactivities that were only 
slightly less active than the ortho-chloro compound 19; the ortho-methoxy 
compound 31 had zones of inhibition of 23-32 mm while the ortho-methyl 
compound 32 had zones of inhibition of 20-27 mm. Compounds 36, 37, 38, and 
39 all contained electron donating groups at the para position, and had 
significantly lower anti-MRSA activity than ortho-substituted compounds 31 and 
32, with zones of inhibition of 10-14 mm for para-acetoxy compound 35, 10-14 
mm for para-acryloxy compound 36, 14-19 mm for para-hydroxy compound 37, 
and 8-12 mm for para-phenyl compound 38. This is again consistent with the 
previously observed trend that the ortho-substituted compounds have higher 
bioactivities. Compound 39, disubstituted with benzyl ether groups at both the 
meta and para positions, displayed activity similar to that of the para-substituted 
analogues 35-38. 
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Table 2.1 Average growth inhibition zones for C4 aryl derivatives against 
MRSA12 
 
Pen
Van
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
8
16
30
25
26
27
21
25
34
23
27
22
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24
29
23
18
17
13
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14
10
13
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15
29
28
26
28
24
27
29
23
24
21
21
23
32
27
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12
12
19
11
12
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16
28
22
26
25
18
22
27
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24
21
19
23
27
23
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16
11
13
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10
13
14
16
27
23
25
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18
21
28
24
24
24
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22
27
23
22
14
14
12
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10
13
12
21
27
23
25
26
19
25
29
22
25
19
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28
25
22
18
13
13
19
11
14
12
15
25
22
23
26
21
25
28
25
24
20
21
22
27
23
20
18
12
14
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12
13
19
15
27
19
24
25
18
23
28
23
20
21
19
20
26
22
21
17
12
13
18
9
11
15
15
23
18
18
21
17
20
23
22
17
17
16
18
23
20
18
11
10
10
0
8
10
nd
nd
28
26
25
26
20
26
29
24
23
22
19
23
27
23
20
18
12
13
17
10
14
MRSA
652
MRSA
653
MRSA
654
MRSA
655
MRSA
656
MRSA
657
MRSA
658
MRSA
659
MRSA
919
Cmpd
#
The values indicate the diameter in mm for the zone of growth inhibition after 24 h of incubation at 37 oC. 
Twenty micrograms of each test compound in DMSO solution was used. All of the microbes listed are β−
lactamase producing, methicillin-resistant strains of Staphylococcus aureus (MRSA). Those labelled as 
MRSA 652-659 were obtained from a clinical testing laboratory at Lakeland Regional Medical Center, 
Lakeland, FL. MRSA 919 is ATCC 43300 and was purchased from American Type Culture Collections. 
Error values are within +/-1 mm. Penicillin G (Pen) and Vancomycin (Van) are included for reference. (nd, 
not determined).  
 
The results of the anti-MRSA studies on the N-organothio analogues13 that 
were presented in Chapter 1 (Figure 1.5) are shown in Table 2.2.  
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Table 2.2 Average growth inhibition zones for N-organothio derivatives 
against MRSA13 
 
 
40
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33
30
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13
33
44
10
24
27
28
22
11
0
33
30
24
12
32
41
10
24
24
27
21
10
0
29
28
24
13
31
39
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23
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27
29
9
0
29
28
22
12
29
39
10
23
22
27
19
9
0
30
27
23
12
30
39
10
22
23
26
19
8
0
30
27
24
14
31
40
10
23
24
27
20
10
0
31
28
25
13
32
41
10
26
25
29
21
9
0
29
27
24
13
30
39
10
24
24
27
19
8
0
31
28
25
14
31
40
10
24
25
28
20
10
0
MRSA
652
MRSA
653
MRSA
654
MRSA
655
MRSA
656
MRSA
657
MRSA
658
MRSA
659
MRSA
919
Cmpd
#
The values indicate the diameter in mm for the zone of growth inhibition after 24 h of incubation at 37 oC. 
Twenty micrograms of each test compound in DMSO solution was used. All of the microbes listed are β−
lactamase producing, methicillin-resistant strains of Staphylococcus aureus (MRSA). Those labelled as 
MRSA 652-659 were obtained from a clinical testing laboratory at Lakeland Regional Medical Center, 
Lakeland, FL. MRSA 919 is ATCC 43300 and was purchased from American Type Culture Collections. 
Error values are within +/-1 mm.  
 
 Compounds 19, 40, 41, 42 and 43 all contain a linear alkyl chain varying 
in length from 1-8 carbons as the substituent on the sulfur atom. The N-ethylthio 
lactam 40 is slightly more active than the lead compound, N-methylthio lactam 19 
(zones of inhibition of 29-33 mm for 40 as compared to 23-30 mm for 19). 
Increasing the carbon chain length beyond 2 carbon atoms led to a systematic 
drop in the bioactivity, with zones of inhibition of 27-30 mm for N-propylthio 
lactam 41, 22-25 mm for N-butylthio lactam 42, and 12-14 mm for N-octylthio 
lactam 43. Lactams 44, 45, 46, 47, 48, and 49 were prepared to study the effect 
of branching in the N-alkylthio substituent on the anti-MRSA activity. Of these five 
compounds, N-isopropylthio analogue 44 and the N-sec-butylthio analogue 45 
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showed excellent bioactivities, with zones of inhibition of 29-33 mm for 44, and 
39-44 mm for 45! The zones of inhibition of the N-sec-butylthio lactam was found 
to be ~ 100% larger than those of Vancomycin, and ~ 200% larger than those of 
Penicillin G against the nine MRSA strains! When the degree of branching in the 
alkylthio side chain was increased farther, as in the N-tert-butylthio lactam 46, the 
bioactivity dropped dramatically to zones of inhibition of only 10 mm. The N-
cyclohexylthio lactam 47, the N-phenylthio lactam 48, and the N-benzylthio 
lactam 49 all had moderate to high bioactivities with zones of inhibition of 22-26 
mm, 22-27 mm, and 26-29 mm respectively. The effect of the oxidation state of 
the sulfur was also examined. It was found that the bioactivity of the lactams 
dropped dramatically with increasing oxidation state of the sulfur: the zones of 
inhibition for the sulfinyl compound 50 were 19-29 mm, for the sulfonyl compound 
51 8-11 mm, and for the sulfonic acid compound 52, 0 mm, indicative of an 
analogue completely devoid of anti-MRSA activity. 
The results of the anti-MRSA studies on the C3 monosubstituted 
analogues that were presented in Chapter 1 (Figure 1.6), and the four new C3 
monosubstituted analogues described in this chapter, 73-76 are shown in Table 
2.3. Compound 19 is the C3 methoxy compound, which is the lead compound for 
our studies on the effect of the C3 substituent on anti-MRSA activity. 
Replacement of the methoxy substituent with either an azide group as in 
compound 55 or an iodine as in compound 56 dropped the zones of growth 
inhibition down to 19-23 mm and 20-25 mm respectively. A chlorine at the C3 
position 57 gave slightly better activity (29-31 mm) than the methoxy compound 
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19. Another interesting thing that should be noted about compounds 55, 56, and 
57, is that they all have a trans relationship of the hydrogens of the β-lactam ring. 
The fact that these compounds show good biological activity demonstrates that a 
cis relationship of the β-lactam ring hydrogens is not required for bioactivity.  
Installation of an amino group at the C3 position (58, 59, 60, and 61) 
eliminated the anti-MRSA activity for the most part. Only the benzylamine 
compound 59 had any anti-MRSA activity at all, and it was very weak (10-12 
mm).   
The C3 alkoxy analogues (62, 74, 75, and 76) all showed greater MRSA 
activity than Penicillin G, but slightly lower than that of the C3-methoxy lactam 
19. The slightly more lipophilic ethers 74 and 75 showed better activity (both 20-
24 mm) than the more polar compounds 62 and 76 (13-16 mm and 15-19 mm 
respectively). Acetoxy compound 63 and hydroxy compound 73 also showed 
slightly lower activities than the C3-methoxy compound 19 (15-24 mm and 17-19 
mm respectively). For the C3 sulfonate compounds 64, 65 and 66, their activities 
increased with increased lipophilicity, with the methyl< phenyl< p-tolyl.  
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Table 2.3 Average growth inhibition zones for C3 monosubstituted 
derivatives against MRSA12 
 
55
56
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74
75
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0
11
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0
16
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21
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0
12
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0
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0
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0
14
23
14
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17
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29
0
10
0
0
16
22
15
16
20
18
23
21
18
21
24
31
0
11
0
0
13
20
15
16
19
16
20
20
18
23
25
30
0
10
0
0
15
21
15
15
20
19
20
20
18
22
23
30
0
10
0
0
16
15
14
15
21
18
24
24
16
23
24
29
0
11
0
0
16
18
15
16
21
18
22
23
15
MRSA
652
MRSA
653
MRSA
654
MRSA
655
MRSA
656
MRSA
657
MRSA
658
MRSA
659
MRSA
919
Cmpd
#
The values indicate the diameter in mm for the zone of growth inhibition after 24 h of incubation at 37 oC. 
Twenty micrograms of each test compound in DMSO solution was used. All of the microbes listed are β−
lactamase producing, methicillin-resistant strains of Staphylococcus aureus (MRSA). Those labelled as MRSA 
652-659 were obtained from a clinical testing laboratory at Lakeland Regional Medical Center, Lakeland, FL. 
MRSA 919 is ATCC 43300 and was purchased from American Type Culture Collections. Error values are within 
+/-1 mm.  
 
 
The results for the screening of the C3 disubstituted analogues against 
MRSA are shown in Table 2.4.  
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Table 2.4 Average growth inhibition zones for C3 disubstituted derivatives 
against MRSA12 
 
77
78
79
67
68
69
70
71
72
28
28
18
25
28
20
22
17
17
26
26
17
26
27
20
19
18
16
24
24
17
22
26
18
20
15
15
26
26
18
23
26
20
21
16
17
26
26
17
25
28
21
20
17
16
26
25
18
26
29
21
28
15
14
24
25
16
24
26
20
17
16
12
26
25
18
21
24
20
21
14
14
27
29
19
24
27
21
21
18
16
MRSA
652
MRSA
653
MRSA
654
MRSA
655
MRSA
656
MRSA
657
MRSA
658
MRSA
659
MRSA
919
Cmpd
#
The values indicate the diameter in mm for the zone of growth inhibition after 24 h of incubation at 37 oC. 
Twenty micrograms of each test compound in DMSO solution was used. All of the microbes listed are β−
lactamase producing, methicillin-resistant strains of Staphylococcus aureus (MRSA). Those labelled as 
MRSA 652-659 were obtained from a clinical testing laboratory at Lakeland Regional Medical Center, 
Lakeland, FL. MRSA 919 is ATCC 43300 and was purchased from American Type Culture Collections. 
Error values are within +/-1 mm.  
 
Compounds 77, 78 and 79 all had a methyl substituent and an alkoxy 
group at C3. As was the case for their corresponding monosubstituted analogues 
(74, 75 and 76), the more lipophilic allyl and propyl ethers had greater activity 
(24-28 mm for 77, and 24-29 mm for 78) than the more polar methoxymethyl 
ether 79 (16-18 mm). The activities for all three of these compounds were higher 
than that of the corresponding monosubstituted analogues. For the next three 
compounds, 67, 68, and 69, the ether was replaced with an acetoxy ester, while 
the alkyl or aryl side chain was varied. Compounds having alkyl side chains, allyl 
(compound 67), and propyl (compound 68), both showed larger zones of growth 
inhibition than the phenyl side chain compound 69. All of these three compounds 
showed greater activity than compound 63- the C3 monosubstituted acetoxy 
analogue. The last three disubstituted analogues, 70, 71, and 72, all contained a 
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spirocyclic ether at the C3 position, and slightly lower activity than the non-
spirocyclic C3 disubstituted ethers. This slight difference in bioactivity is likely 
due to the fact that the aryl ring at the C4 position of these compounds is also 
different. Compounds 70 and 71 have a phenyl at C4 and compound 72 has a 
para-nitrophenyl at the C4 position. 
 
2.2.5 Results of biological screening against Bacillus10 
 
The results for the screening of the N-thiolated β-lactam analogues against the 
seven strains of Bacillus are shown in Tables 2.5, 2.6, 2.7, and 2.8. Table 2.5 
shows the results of the screening of the C4 aryl analogues, Table 2.6 shows the 
results of the screening for the N-organothio analogues and the reference drug 
ciprofloxacin, Table 2.7 shows the results for the screening of the C3 
monosubstituted analogues, and Table 2.8 shows the results of the screening of 
the C3 disubstituted analogues, The trends observed in the screening of these 
compounds against Bacillus almost exactly parallel the trends that were 
observed in the screening against MRSA, and therefore do not need to be 
discussed again in detail. The similar activity trends observed for Bacillus and 
MRSA suggest that the mode of action of the N-thiolated β-lactams against both 
of these bacterial species is similar.  
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Table 2.5 Average growth inhibition zones for C4 aryl derivatives against 
Bacillus 
 
Cip
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
36
B.
anthracis
Cmpd B.
globigii
B.
thuringensis
B.
megaterium
B.
coagulans
B.
subtilis
B.
cereus
39
25
25
20
25
25
20
25
22
22
27
24
20
nd
21
22
10
20
33
18
18
19
18
19
17
17
19
20
22
16
20
14
14
16
10
19
40
19
19
20
19
18
17
17
15
19
20
17
20
13
15
17
0
16
41
16
16
18
17
17
15
15
11
17
21
19
20
10
12
14
0
15
42
20
20
15
15
18
16
13
13
22
17
14
22
13
15
17
0
10
41
18
15
10
12
12
10
14
14
18
21
12
18
0
10
17
0
19
33
21
20
0
20
20
18
19
19
23
21
19
20
nd
18
18
17
15
Twenty micrograms of test compound in DMSO solution was used in each case. The values indicate the diameters 
in mm for the zone of growth inhibition obtained for each compound after 24 h of incubation at 37 oC. Error values 
are within +/- 1mm. Ciprofloxacin (cip) is included for reference. (nd, not determined).
 
 
Table 2.6 Average growth inhibition zones for N-organothio derivatives 
against Bacillus 
 
45
52a
53
54
B.
anthracis
Cmpd B.
globigii
B.
thuringensis
B.
megaterium
B.
coagulans
B.
subtilis
B.
cereus
40
0
10
10
39
0
10
0
30
0
0
9
36
0
0
10
37
0
0
0
39
0
0
nd
30
0
0
nd
Twenty micrograms of test compound in DMSO solution was used in each case. The values indicate the diameters 
in mm for the zone of growth inhibition obtained for each compound after 24 h of incubation at 37 oC. Error values 
are within +/- 1mm. a tested as the tetra n-butyl ammonium salt. (nd, not determined).  
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Table 2.7 Average growth inhibition zones for C3 monosubstituted 
derivatives against Bacillus 
 
55
56
57
58
59
60
61
62
64
65
66
73
74
75
76
B.
anthracis
Cmpd B.
globigii
B.
thuringensis
B.
megaterium
B.
coagulans
B.
subtilis
B.
cereus
20
22
22
0
10
0
0
20
10
18
19
24
27
27
20
14
24
22
0
9
0
0
18
8
15
12
14
20
24
15
18
15
14
0
9
0
0
11
10
13
11
19
20
19
15
20
13
11
0
7
0
0
12
0
15
11
17
22
20
15
15
11
15
0
0
0
0
18
10
nd
13
17
21
19
15
18
13
14
0
0
0
0
19
10
nd
12
11
23
22
19
21
17
17
0
11
0
0
22
14
nd
13
19
23
22
19
Twenty micrograms of test compound in DMSO solution was used in each case. The values indicate the diameters 
in mm for the zone of growth inhibition obtained for each compound after 24 h of incubation at 37 oC. Error values 
are within +/- 1mm. (nd, not determined).  
 
 
Table 2.8 Average growth inhibition zones for C3 disubstituted derivatives 
against Bacillus 
 
70
77
78
79
B.
anthracis
Cmpd B.
globigii
B.
thuringensis
B.
megaterium
B.
coagulans
B.
subtilis
B.
cereus
14
29
28
20
10
25
26
15
9
20
21
16
9
22
22
16
13
20
20
15
0
21
17
13
17
22
21
18
Twenty micrograms of test compound in DMSO solution was used in each case. The values indicate the diameters 
in mm for the zone of growth inhibition obtained for each compound after 24 h of incubation at 37 oC. Error values 
are within +/- 1mm. (nd, not determined).  
 
2.3 Conclusions 
 In conclusion, it was found that slightly lipophilic acyloxy or alkoxy groups 
at the C3 position of the lactam ring lead to larger zones of growth inhibition for 
both MRSA and Bacillus. Also, the stereochemistry at this position does not 
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seem to be related to the bioactivities of these compounds. At the C4 position, 
aromatic rings that bear a halogen or a small, electron-donating group at the 
ortho position of the ring leads to the greatest anti-MRSA and anti-Bacillus 
activity. The most dramatic effects on the bioactivity against both MRSA and 
Bacillus was seen when the N-alkylthio group was varied, with the N-sec-
butylthio lactam having the strongest bioactivity of any N-thiolated β-lactam 
analogues prepared in our laboratory to date.  
 All of these observed trends in the bioactivities lead us to believe that the 
bioactivity of these N-thiolated β-lactams is due to the transfer of the N-
organothio group to a thiol target in the cell. The role of the C3 and C4 rings 
substituents is likely to aid in the transport of the β-lactam molecule across the 
lipid bilayer of the bacterial cell membrane. The parallels in the activity trends 
against MRSA and Bacillus suggest that the mode of action of the N-thiolated β-
lactams against both of these bacterial species is similar.  
This chapter focused on the synthesis of seven C3 oxygenated 
analogues. From the results of the screening of these seven C3 analogues as 
well as other C3 analogues, it was determined that as long as the substituent 
possesses  the proper lipophilic/polar balance, we can introduce different groups 
at this position and still retain the bioactivity. This is important to know in terms of 
our interest in attaching these N-thiolated β-lactams to polymers and oligomers to 
form new biomaterials. Since such a wide variety of groups can be tolerated at 
the C3 position, this position was selected as an ideal site for attachment. Efforts 
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towards the synthesis of N-thiolated β-lactam containing biomaterials will be 
discussed in the upcoming chapters. 
 
 
2.4 Experimental 
 
All reagents needed for the synthesis of N-thiolated β-lactams analogues were 
purchased from Sigma-Aldrich Company or Fisher Scientific and used without 
further purification unless otherwise stated.  Solvents were obtained from Fisher 
Scientific and used without further purification.  Products were purified by flash 
column chromatography with J. T. Baker flash chromatography silica gel (200-
400 mesh). NMR spectra were recorded in CDCl3. 13C NMR spectra were proton 
decoupled. 
 
Synthesis of imine 82: p-anisidine was recrystallized from water prior to use. O-
chlorobenzaldehyde (42.23 g, 0.3mol) was added to p-anisidine (37.0 g, 0.3mol) 
and stirred with a glass rod until a yellow paste formed. The crude product was 
recrystallized from methanol to yield 67.34g (91%) of imine as a yellow solid, 
m.p. 62-63 oC. 1H NMR (250 MHz): δ 8.95 (1H, s), 8.27-8.23 (1H, m), 7.45-7.36 
(3H, m), 7.30 (2H, d, J=8.9Hz), 6.96 (2H, d, J=8.9Hz) 3.86 (3H, s); 13C NMR: (63 
MHz) δ 156.5, 154.6, 144.5, 135.7, 133.3, 131.7, 129.8, 128.3, 127.0, 122.4, 
114.8, 114.3, 55.9 
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Synthesis of β-lactam 84: Imine 82 (5.8 g 23.6 mmol) was dissolved in 100 mL of 
freshly distilled CH2Cl2 and cooled to 0oC in an ice bath. Triethylamine was 
added (3. eq., 7.16 g, 70.8 mmol) was added, followed by acetoxy acetyl chloride 
(1.8 eq., 5.8 g, 42.5 mmol) dissolved in 20 mL of CH2Cl2. The reaction was 
stirred overnight. The solvent was removed under reduced pressure and the 
crude material was purified by washing with ice-cold methanol to give 7.1 g (87 
%) of lactam 84 as a white solid, m.p. 130-131 oC. 1H NMR (250 MHz): δ 7.43 ( 
1H, d, J=8.9 Hz), 7.32-7.23 (5H, m), 6.83 (2H, d, J=8.9 Hz), 6.16 (1H, d, J=5.0 
Hz), 3.76 (3H, s), 1.76 (3H, s). 
 
Synthesis of lactam 85: Lactam 84 (2.0g, 5.78 mmol) was dissolved in 60 mL of 
acetonitrile and cooled to 0oC in an ice bath. CAN (9.54g, 11.7 mmol) was 
dissolved in 15 mL of water and added to the lactam solution dropwise, over the 
period of one hour. The reaction mixture was then extracted three times with 25 
mL of ethyl acetate. The combined ethyl acetate layers were washed with 50 mL 
of 5% NaHSO3, 50 mL of 5% NaHCO3, and 50 mL of brine, and dried over 
Na2SO4. The solvent was removed under reduced pressure. The crude product 
was purified by flash column chromatography using 4:1 hexanes to ethyl acetate 
as the eluent to give 0.83 g (60%) of 85 as a light yellow solid. 1H NMR (250 
MHz): δ 7.42-7.23 (4H, m), 6.46 (1H, br. s), 6.21 (1H, d, J=5.0 Hz),  5.42 (1H, d, 
J=5.0 Hz), 1.76 (3H, s). 
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Synthesis of lactam 63: Lactam 85 (2.0g, 8.35 mmol) was dissolved in 100 mL of 
CH2Cl2, and 86 (1.70g, 8.35 mmol) was added along with a catalytic amount of 
triethylamine. The reaction was refluxed overnight and then the solvent was 
removed under reduced pressure. The crude product was purified by flash 
column chromatography using 9:1 hexanes to ethyl acetate as the eluent to give 
1.67 g (70%) of 63 as a light yellow solid. 1H NMR (250 MHz): δ 7.42-7.23 (4H, 
m), 6.08 (1H, d, J= 5.0Hz),  5.42 (1H, d, J= 5.0Hz), 2.51 (3H, s),1.76 (3H, s).  
 
Synthesis of 73: Lactam 63 (0.20g, 0.7mmol) was dissolved in 5 mL of methanol 
and potassium carbonate (0.7mmol as a 1M solution in water) was added. After 1 
minute, the reaction mixture was extracted three times with 10 mL of ethyl 
acetate, and then the combined ethyl acetate layers were washed with 30mL of 
brine, dried over Na2SO4, and the solvent removed under reduced pressure to 
give 73 (0.143g, 78%) as a white solid. 1H NMR (250 MHz): δ 7.42-7.23 (4H, m), 
5.28 (1H, d, J=5.0 Hz),  5.24 (1H, d, J=5.0 Hz), 2.51 (3H, s),1.76 (3H, s). 13C 
NMR: (63 MHz) δ 171.7, 133.8, 131.4, 130.0, 129.8, 128.3, 127.1, 79.1, 63.9, 
21.8. 
 
Synthesis of 87: To a solution of 84 (1.23g, 3.56 mmol) in 30 mL of acetone was 
added a solution of KOH in methanol at 0 oC. After 5 minutes, the reaction was 
quenched by adding an equal volume of water to precipitate the product out of 
solution. The product was filtered and dried to give 1.07g (99%) of a white solid, 
m.p. 183-184 oC. 1H NMR (250 MHz): δ 7.48 (1H, d, J=7.5 Hz), 7.33-7.22 (5 H, 
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m), 6.84 (2H, d, J=7.5 Hz), 5.63 (1H, d, J=5.1 Hz), 5.33 (1H, d, J=5.1 Hz), 3.78 
(3H,s), 2.00 (1H, br.s).  
 
Synthesis of lactam 88: To a solution of lactam 87 (1.0 g, 3.3 mmol) in 25 mL of 
dry CH2Cl2 was added NaH (60% suspension in mineral oil, 0.26 g, 6.6 mmol) 
and the mixture was stirred for 15 min. Allyl bromide (0.79 g, 6.6 mmol) was then 
added, along with 5 mg of TBAI. The mixture was refluxed for 24 h and then 
quenched with a 5% solution of NH4Cl. The solution was extracted three times 
with 25 mL of CH2Cl2 and then the combined CH2Cl2 layers were washed with 
brine, dried over Na2SO4, and the solvent was removed under reduced pressure. 
The crude material was purified by flash column chromatography using 9:1 
hexanes to ethyl acetate as the eluent to give 0.92 g (85%) of 88 as a light yellow 
solid, m.p. 61-63 oC. 1H NMR (250 MHz): δ 7.43 (1H, d, J=9.0 Hz), 7.40-7.20 
(5H, m), 6.80 (2H, d, J=9.0 Hz), 5.61 (1H, d, J=4.7 Hz), 5.09 (2H, d, J=5.9 Hz), 
5.02 (1H, d, J=4.7 Hz), 3.92 (2H, d, J=5.9 Hz), 3.73 (3H, s); 13C NMR: (63 MHz) 
δ 163.8, 156.3, 133.2, 133.0, 131.2, 130.3, 129.0, 126.9, 118.1, 114.3, 82.5, 
71.9, 58.9, 55.4. 
 
Lactam 89: off-white solid, m.p. 119-121 oC, 87% yield. 1H NMR (250 MHz): δ 
7.42 (1H, d, J=7.8 Hz), 7.38-7.22 (5H, m), 6.80 (2H, d, J=7.8 Hz), 5.64 (1H, d, 
J=5.0 Hz), 5.21 (1H, d, J=5.0 Hz), 4.56 (2H, s), 3.74 (3H, s), 3.19 (3H,s); 13C 
NMR: (63 MHz) δ 163.9, 156.4, 133.3, 131.5, 130.4, 129.5, 126.9, 118.6, 114.4, 
96.6, 80.4, 58.9, 55.7, 55.4. 
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Lactam 90: Brown semi-solid, 69% yield. 1H NMR (250 MHz): δ 7.50-7.26 (4H, 
m), 6.25 (1H br. s.), 5.70-5.55 (1H, m), 5.26 (1H, d, J=4.6 Hz), 5.11-5.00 (2H, m), 
4.97 (1H, d, J=4.6 Hz), 3.93-3.89 (2H, m); 13C NMR: (63 MHz) δ 168.7, 133.8, 
133.2, 129.1, 128.4, 126.9, 117.8, 84.6, 71.8, 56.0. 
 
Lactam 91: 97 % yield  1H NMR (250 MHz): δ 7.49 (1H, m) 7.46-7.26 (3H, m), 
6.30 (1H br. s.), 5.26 (1H, d, J=4.6 Hz), 4.91 (1H, d, J=4.6 Hz), 3.47-3.38 (1H, 
m);  3.25-3.19 (1H, m), 1.33-1.24 (2H, m), 0.54 (3H, m) 13C NMR: (63 MHz) δ 
168.6, 133.9, 133.0, 129.2, 129.0, 128.4, 126.8, 85.8, 43.1, 56.1, 22.6, 10.0. 
 
Lactam 92: 64 % yield .1H NMR (250 MHz): δ 7.48-7.26 (4H, m), 6.26 (1H, br. s), 
5.29 (1H, d, J=5.0 Hz), 5.17 (1H, d, J=5.0 Hz), 4.55 (2H, s), 3.21 (3H,s); 13C 
NMR: (63 MHz) δ 169.3, 133.3, 129.9, 128.7, 128.5, 127.7, 126.8, 96.1, 84.2, 
57.3, 50.2. 
 
Lactam 74: 25% yield. 1H NMR (250 MHz): δ 7.39-7.26 (4H, m), 5.62-5.51 (1H, 
m), 5.34 (1H, d, J=4.8 Hz), 5.06-5.03 (2H, m), 4.99 (1H, d, J=4.8 Hz), 3.93-3.78, 
(2H, m), 2.45 (3H, s); 13C NMR: (63 MHz) δ 170.4, 133.7, 132.8, 131.6, 129.5, 
129.4, 129.1, 126.7, 118.0, 84.4, 71.6, 62.8, 21.7. 
 
Lactam 75: 40% yield. 1H NMR (250 MHz): δ 7.34 (1H, m) 7.27-7.24 (3H, m), 
5.31 (1H, d, J=4.8 Hz), 4.91 (1H, d, J=4.8 Hz), 3.38-3.32 (1H, m);  3.09-3.04 (1H, 
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m), 2.42 (3H, s),1.27-1.19 (2H, m), 0.49 (3H, m) 13C NMR: (63 MHz) δ 170.5, 
134.6, 133.8, 131.6, 129.4, 129.1, 126.6, 85.6, 72.9, 63.0, 22.4, 21.8, 10.0. 
 
Lactam 76: 35% yield. 1H NMR (250 MHz): δ 7.39-7.26 (4H, m), 5.37 (1H, d, 
J=5.1 Hz), 5. 19 (1H, d, J=5.1 Hz), 4.51 (2H, s), 3.14 (3H, s), 2.47 (3H, s) ; 13C 
NMR: (63 MHz) δ 170.6, 134.6, 131.8, 129.5, 129.4, 128.8, 126.8, 96.3, 82.8, 
62.8, 55.7, 21.7. 
 
Synthesis of lactam 93: P2O5 (0.75 g, 2.47 mmol) was added to 10 mL of DMSO 
and allowed to stir for 10 minutes. After 10 min, lactam 87 (0.75 g, 2.47 mmol) 
was added to the solution. After stirring at room temperature overnight, the 
reaction was quenched with a saturated NaHCO3 solution. The mixture was then 
extracted three times with 15 mL of ethyl acetate. The combined ethyl acetate 
layers were washed with water, dried over Na2SO4, and the solvent was removed 
under reduced pressure to give 0.71 (96 %) of 93 as a yellow solid, m.p. 130-132 
oC. 1H NMR (250 MHz): δ 7.49-7.38 (3H, m), 7.36-7.16 (4H, m), 6.89-6.82 (2H, 
m), 6.05 (1H, s), 3.72 (3H, s); 13C NMR: (63 MHz) δ 189.6, 160.0, 158.0, 133.4, 
130.7, 130.6, 129.7, 129.4, 127.7, 127,5, 119.7, 114.0, 72.0, 55.5. 
 
Synthesis of lactam 94: All glassware was flame-dried under nitrogen 
atmosphere prior to use. Lactam 93 was dissolved in freshly distilled THF. The 
flask was flushed with nitrogen and cooled to -78oC using a dry ice/acetone bath. 
Methylmagnesium iodide (0.35g, 2.5 mmol) (generated in a separate flask from 
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Mg ribbon, methyl iodide, and a catalytic amount of iodine) was cooled to -78oC, 
and then the ketone solution was added to the flask containing the freshly 
prepared grignard reagent. The reaction was stirred at -78 oC for 3 hours, and 
then was allowed to warm to room temperature. The reaction was quenched with 
5% NH4Cl, extracted three times with ethyl acetate, washed with water, dried 
over Na2SO4 and the solvent was removed under reduced pressure to give 0.39g 
(74%) of 94 as a light brown solid, m.p. 141-143 oC. 1H NMR (250 MHz): δ 7.49-
7.38 (1H, m), 7.36-7.16 (5H, m), 6.89-6.82 (2H, m), 5.38 (1H, s), 3.75 (3H, s) 
1.83 (3H, s); 13C NMR: (63 MHz) δ 168.2, 156.5, 133.5, 132.1, 130.5, 129.8, 
129.4, 128.1, 127.0, 118.8, 114.4, 84.0, 66.2, 55.5, 22.0. 
 
Lactam 95: 87% yield. 1H NMR (250 MHz): δ 7.44-7.41 (1H, m), 7.29-7.16 (5H, 
m), 6.83-6.80 (2H, m), 5.46-5.35 (1H, m), 5.35 (1H, s), 4.86-4.80 (2H, m) 3.89-
3.87 (2H, m) 3.74 (3H, s) 1.81 (3H, s); 13C NMR: (63 MHz) δ 166.0, 156.3, 133.6, 
133.3, 132.1, 130.6, 129.4, 129.1, 128.7, 126.6, 118.6, 116.0, 114.3, 88.5, 66.9, 
65.4, 19.41. 
 
Lactam 96: 80% yield. 1H NMR (250 MHz): δ 7.45-7.41 (1H, m), 7.29-7.11 (5H, 
m), 6.83-6.80 (2H, m), 5.26 (1H, s), 4.53 (2H, s), 3.69 (3H, s), 3.040 (3H, s), 1.78 
(3H, s) ; 13C NMR: (63 MHz) δ 165.9, 156.5, 133.5, 132.4, 130.7, 129.6, 129.2, 
128.7, 126.8, 118.7, 114.5, 93.2, 87.4,65.6, 55.7, 55.5, 20.4. 
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Lactam 97: 74% yield. 1H NMR (250 MHz): δ 7.48-7.26 (5H, m), 6.25 (1H, br s), 
5.39-5.35 (1H, m), 4.97 (1H, s), 4.86-4.77 (2H, m) 3.82-3.79 (2H, m), 1.80 (3H, 
s); 13C NMR: (63 MHz) δ 170.5, 134.5, 133.7, 133.1, 129.2, 128.8, 127.8, 126.6, 
116.0, 90.8, 66.8, 62.6, 19.6 
 
Lactam 98: 98% yield. 1H NMR (250 MHz): δ 7.45-7.16 (5H, m), 6.95 (1H, br s), 
4.82 (1H, s), 3.21-3.03 (2H, m), 1.64 (3H, s) 1.09-1.01 (2H, m), 0.49 (3H, t); 13C 
NMR: (63 MHz) δ 171.40, 134.9, 133.2, 129.3, 128.8, 128.2, 127.2, 126.6, 90.8, 
67.7, 62.8, 22.9, 19.87, 9.99. 
 
Lactam 99: 95% yield. 1H NMR (250 MHz): δ 7.43-7.32 (2H, m), 7.29-7.24 (2H, 
m), 6.60 (1H, br s), 4.94 (1H, s), 4.54 (2H, s), 3.06 (3H, s), 1.80 (3H, s) ; 13C 
NMR: (63 MHz) δ 170.2, 134.7, 133.1, 129.2, 128.9, 127.8, 126.7, 93.0, 90.0, 
62.6, 55.6, 20.3. 
 
Lactam 77: 38% yield. 1H NMR (250 MHz): δ 7.40-7.26 (4H, m), 5.41-5.34 (1H, 
m), 5.05 (1H, s), 4.84-4.77 (2H, m) 3.83-3.75 (2H, m), 2.48 (3H, s),1.73 (3H, s); 
13C NMR: (63 MHz) δ 169.7, 133.8, 129.7, 129.5, 128.9, 126.9, 116.4, 69.5, 67.1, 
21.5, 19.1. 
 
Lactam 78: 54% yield. 1H NMR (250 MHz): δ 7.36-7.28 (4H, m), 4.82 (1H, s), 
3.33-3.29 (1H, m), 3.04-3.01 (1H, m), 2.40 (3H, s), 1.61 (3H, s) 1.23-1.14 (2H, 
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m), 0.59 (3H, t); 13C NMR: (63 MHz) δ 173.1, 133.9, 132.7, 129.5, 129.2, 128.7, 
126.6, 90.7, 69.4, 67.6, 22.8, 21.2, 19.0, 10.0. 
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Chapter 3 
Functionalized Caprolactone Monomers: Design, Synthesis, and Biological 
Evaluation 
 
3.1 Introduction 
 
 Many MRSA infections occur at the site of an injury, such as a cut in the 
skin where bacteria can enter the body. It makes sense then to try to find a way 
to effectively deliver the antibacterial drugs directly at the site of an injury, where 
water-soluble penicillins may not work well. Previous results from Chapter two 
have shown us that many different alkoxy and hydroxyl groups could be 
incorporated at the C3 position of the lactam ring of N-thiolated β-lactams without 
diminishing anti-MRSA and anti-Bacillus activity. For this reason, this site of the 
lactam ring was selected as an ideal spot for further modification to make new, 
antibacterial materials.  
The material that we choose to try to attach our N-thiolated β-lactams to is 
poly(ε-caprolactone) (100) to form a drug-bearing polymer (101), as shown in 
Figure 3.1.  
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Figure 3.1 Poly(ε-caprolactone) and proposed drug-bearing poly(ε-
caprolactone) 
 
O
O
Drug
101
O
O
100  
 
 
 
Poly(ε-caprolactone) is an aliphatic polyester. Aliphatic polyesters are 
often used as biomaterials because they are biodegradable. Materials that 
biodegrade are attractive for biomedical applications because they do not require 
a second doctor’s visit or surgery to remove, and as such, have found use for 
wound closure (staples, sutures), cardiovascular applications (stents, grafts), and 
orthopedic devices (pins, screws, rods, artificial ligaments).1 
Poly(ε-caprolactone) degrades in vivo by the enzymatic hydrolysis of the 
ester bonds to give 6-hydroxyhexanoic acid, which is then broken down 
systematically through the citric acid cycle2 (Scheme 3.1). The byproducts of this 
degradation are therefore non-toxic, and thus poly(ε-caprolactone) is safe for use 
in the human body. 
 
Scheme 3.1 In vivo degradation of poly(ε-caprolactone) 
O
O
n
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Poly(ε-caprolactone) has a high permeability to many drugs, and as such 
has found a lot of use in drug delivery3, including delivery of the anti-MRSA drug, 
vancomycin, which was encapsulated in the preformed polymer via emulsification 
in water.4 Since poly(ε-caprolactone) lacks functionality on the polymer 
backbone, we decided to synthesize a caprolactone monomer that bore suitable 
functionality where a drug molecule could be covalently bound. The first thing 
that we considered was to have a halide on the caprolactone so that we could 
utilize a Williamson ether synthesis similar to those described in Chapter 2 to 
make the C3 alkoxy analogues. A search of the literature revealed that 5-
bromocaprolactone (103) (Figure 3.2) had been previously synthesized by 
Trollsås et al.5 
 
Figure 3.2 5-bromocaprolactone 
O
O
Br
103  
 
Although at first glance this seemed like a good monomer to try, we decided 
against this system because the bromide was at a secondary carbon center, on 
the nucleophilically-sensitive lactone and ring-opening or elimination to give the 
alkene would be more likely than substitution under the basic conditions of the 
Williamson ether synthesis (Scheme 3.2). It was observed during the syntheses 
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of the C3 alkoxy lactams 74-79 that the alkylation of lactams 87 and 94 required 
the use of highly activated alkylating agents. Allyl bromide and methoxymethyl 
chloride were selected specifically because they were primary, activated, and 
less likely to undergo base-promoted elimination reactions.  
 
Scheme 3.2 Likely outcome of Williamson ether synthesis of lactone 103 
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During the course of the N-thiolated β-lactam SAR study (Chapter 2) other 
compounds that were synthesized contained acyloxy esters at the C3 position. 
These acyloxy compounds could be formed easily under relatively neutral 
conditions. Also, the activity of these esterified compounds was found to be 
comparable to that of the C3 alkoxy derivatives. A further literature result 
revealed that Hedrick et al. had synthesized two caprolactone monomers (106 
and 107) that bore pendant ester groups at the five position of the lactone ring, 
shown in Figure 3.3.6 
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Figure 3.3 Substituted lactones prepared by Hedrick et al. 
O
O
OBnO
O
O
OBuO
t
106 107  
 
With these two monomers, we were concerned that it would be difficult to couple 
the sterically hindered secondary alcohol of the lactam ring with a carboxylic acid 
that had branching at the α-position. Instead, we proposed that introducing an 
additional methylene spacer in between the caprolactone ring and the ester 
substituent (as shown in figure 3.4) would add more degrees of freedom to the 
system to allow for an easier coupling with our lactams. 
 
Figure 3.4 Proposed lactone. 
O
O
CO2R
108  
 
The retrosynthetic analysis for lactone 108 is shown in Scheme 3.3, 
starting from commercially available 1,4-cyclohexadione monoethyleneacetal 
(111). Lactone 108 could be easily formed via a Baeyer-Villiger reaction of the 
corresponding substituted cyclohexanone 109. Cylohexanone 109 could be 
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obtained following the hydrogenation of the Wittig product 110 and deprotection 
of the acetal. We envisioned that a Wittig reaction between ketone 111 and an 
ylide derived from an α-haloacetate would be a facile way of introducing the 
required alkyl ester side chain.  
 
Scheme 3.3 Retrosynthesis for substituted lactone 108 
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3.2 Results and discussion 
 
3.2.1 Synthesis of lactone bearing a pendant benzyl ester 
 
 The first lactone that we decided to synthesize for these studies had a 
pendant benzyl ester substituent at the 5-position of the lactone ring (112, Figure 
3.5). This target was selected because it was envisioned that the benzyl ester 
moiety could be easily deprotected at a suitable point prior to attachment of the 
hydroxyl lactam. 
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Figure 3.5 
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The synthesis of the substituted lactone 112 began with phosphorus ylide 
115. Although commercially available, ylide 115 could be easily prepared in bulk 
as shown in Scheme 3.4. Ethyl bromoacetate (113) was added to a solution of 
triphenylphosphine in benzene, and stirred overnight at room temperature to form 
the phosphonium salt 114 as a white solid. The salt was then filtered and washed 
with benzene to remove any residual triphenylphosphine. Phosphonium salt 114 
was then dissolved in a solution of 20% sodium hydroxide and stirred at room 
temperature for five hours to give the ylide 115. This ylide is stabilized by the 
ester group, and can easily be stored on the shelf for months before use.  
 
Scheme 3.4 Synthesis of ylide 115. 
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113 114 115
Reagents and conditions: (a) PPh3, C6H6, 12h, rt; (b) 20% NaOH(aq), 5h, rt. 
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 The first route that we used to obtain the lactone 112 is shown in scheme 
3.5. First, commercially available 1,4-cyclohexadione monoethyleneacetal (111) 
underwent a Wittig olefination with ylide 115 to give the alkene 116 as a clear, 
colorless liquid in 90-95% yield, after flash column chromatography. Next, the 
alkene was reduced by catalytic hydrogenation to give 117 also as a clear, 
colorless liquid in quantitative yield. Next, both the acetal and the ethyl ester 
were hydrolyzed by stirring at room temperature in dilute sulfuric acid solution. 
Both of the groups could be hydrolyzed to give 118 under these conditions, 
however, there were a number of problems involved in this step. At higher 
concentrations of H2SO4 (5-10% by volume) the yields of the reactions were 
lower (~50-60%) and there was a lot of decomposition of the starting material 
was observed. Lowering the sulfuric acid concentration to 2% eliminated most of 
the decomposition products and increased the yields to ~80-90%, but increased 
the reaction time to ~5 days. Next, the acid 118 was subjected to esterification 
with benzyl bromide under basic conditions to give the required substituted 
cyclohexanone 119 as colorless crystals in 88% yield. The Baeyer-Villiger 
reaction of 119 proceeded very smoothly to give the desired lactone 112 in 90-
95% yield as a colorless oil initially. Drying under vacuum for a few hours 
transformed the oil into a white, somewhat waxy solid with a low melting point of 
59-60 oC. 
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Scheme 3.5 Initial synthesis of lactone 112 
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Reagents and conditions: (a) 2 eq. 115, C6H6, 12h, 
reflux; (b) 60 psi H2(g), cat. 10% Pd/C, MeOH, 12h; 
(c) H2SO4(aq), rt; (d) 3 eq. K2CO3, 1.1 eq. BnBr, MeCN, 
12h, reflux; (e) 1.5 eq. mCPBA, CHCl3, 3-5h, reflux.
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Although this synthetic route was successful in producing the desired 
lactone 112, the yields and reaction conditions for the hydrolysis were 
unsatisfactory. We decided to try to avoid the need to hydrolyze both the ester 
and the acetal in the same step. This could be done by modifying the synthesis 
shown in Scheme 3.5 to break up the hydrolysis reactions into two separate 
steps, as shown in Scheme 3.6.  
 First, intermediate 117 (from Scheme 3.5) was subjected to ester 
hydrolysis under basic conditions using lithium hydroxide in methanol, followed 
by acidic work-up and extraction with diethyl ether to give the free acid 120 as 
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colorless crystals in 75% yield. Next, the acid was esterified with benzyl bromide 
and potassium carbonate to give crude benzyl ester 121 as a clear, colorless oil 
which was taken on directly to the next step without further purification. Next, the 
hydrolysis of the acetal 121 was accomplished by stirring overnight in 70% acetic 
acid. This hydrolysis went smoothly to give the substituted cyclohexanone 119 in 
81 % yield (for the two steps), with none of the decomposition problems that 
were associated with the sulfuric acid hydrolysis. Finally, the substituted lactone 
112 was obtained easily through a Baeyer-Villiger reaction as described before.  
 
Scheme 3.6 Alternate synthesis of lactone 112. 
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Reagents and conditions: (a) 3 eq. LiOH, MeOH, 12h, rt;
1M HCl; (b) 3 eq. K2CO3, 1.1 eq. BnBr, MeCN, 12h, 
reflux; (c) 70 % AcOH, 12-24h, rt; (d) 1.5 eq. mCPBA, 
CHCl3, 3-5h, reflux.  
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3.2.2 Synthesis of lactone 122 bearing an acid-cleavable tert-butyl ester 
group 
 
 A lactone bearing a pendant tert-butyl ester (122, Figure 3.6) was also 
synthesized to have a protecting group that could be easily cleaved later under 
mild acid conditions. 
 
Figure 3.6 
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The synthesis of the lactone 122 began with the synthesis of the 
phosphorus ylide derived from tert-butyl bromoacetate (123). The synthesis of 
this ylide was accomplished in the same fashion as ylide 115 (Scheme 3.7). First, 
the tert-butyl bromoacetate was added to a solution of triphenylphosphine in 
benzene, which was then stirred overnight at room temperature to give the 
phosphonium salt 124 as a white solid. The salt was filtered off and washed with 
benzene to remove any residual triphenylphosphine. The phosphonium salt 124 
was then dissolved in a solution of 20% sodium hydroxide and stirred at room 
temperature for five hours to give the ylide 125 as a sticky, colorless oil that was 
used directly in the next scheme (Scheme 3.8). 
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Scheme 3.7 Synthesis of ylide 125 
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Reagents and conditions: (a) PPh3, C6H6, 12h, rt; (b) 20% NaOH(aq), 5h, rt. 
  
 The synthesis of lactone 122 is shown in Scheme 3.8. The first step was 
the Wittig olefination using the ylide 125 formed in Scheme 3.7, and the 
commercially available 111.  
 
Scheme 3.8 Synthesis of lactone 122 
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Reagents and conditions: (a) 2 eq. 125, C6H6, 12h, reflux; 
(b) H2(g), cat. 10% Pd/C, EtOAc, 24h; (c) 0.1 eq. I2, dry acetone, 1h, rt
(d) 1.5 eq. mCPBA, CHCl3, 3h, reflux.
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This reaction proceeded very smoothly to give the alkene 126 as a clear, 
colorless liquid in 81% yield. Next, the alkene 126 was subjected to catalytic 
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hydrogenation using 10% Pd/C as a catalyst. Curiously, even after 24h, the TLC 
of the reaction mixture still showed two spots. The reaction was stopped at this 
point, and the two compounds were separated via column chromatography. From 
the column, the expected alkane product, 127, was isolated in 57 % yield. The 
second product 128, isolated in 19% yield, was the product expected for the next 
step, where the ketal was deprotected! It seems most likely that there was an 
acidic contaminant present during the hydrogenation reaction that led to the 
deprotection of the ketal. For the deprotection of the isolated ketal 127, care had 
to be taken to select conditions that would not also remove the acid-labile tert-
butyl ester. A literature search revealed a mild method of removing acetals and 
ketals using molecular iodine in dry acetone that was published in 2004 by Sun 
et al.7 The deprotection of ketal 127 following the procedure of Sun proceeded in 
1h to give ketone 128 as colorless crystals, m.p. 36-38 oC, in 50% yield. 
Extending the reaction time beyond 1h did not improve the yield. Heating the 
reaction led to the formation of side products (as observed by the formation of 
multiple spots on the TLC plate). However, in spite of the somewhat low yield, 
this method of deprotecting the ketal works well for this system because the 
unreacted ketal can be easily recovered by column chromatography and recycled 
through the deprotection reaction again. Following the ketal deprotection, the 
ketone 128 proceeded smoothly through the Baeyer-Villiger reaction to give the 
desired lactone 122 as colorless crystals, m.p. 82-83 oC, in 83-97% yield.  
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 The proposed mechanism for the ketal deprotection using molecular 
iodine in acetone is shown in Figure 3.7. In this reaction, acetone serves as both 
the solvent and the substrate. Sun proposed that the deprotection proceeds via a 
substrate exchange mechanism, rather than through a hydrolysis mechanism. A 
previous report by Firouzabadi et al involving the iodine-catalyzed 
transthioacetalization of O,O-acetals8 supports this hypothesis. 
 
 
Figure 3.7 Proposed mechanism of ketal deprotection using molecular 
iodine in acetone7 
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3.2.3 Attachment of N-thiolated β-lactams  
  
The two new ester-substituted lactones 108 and 122 were deprotected as 
shown in Schemes 3.9 and 3.10 in order to attach the lactam drug onto the 
lactone framework. The benzyl ester 112 was deprotected using catalytic 
hydrogenation to give the free acid 129 as a colorless oil in nearly quantitative 
yield. The tert-butyl ester was deprotected using a equivolume mixture of 
methylene chloride and trifluoroacetic acid (TFA) to give 129 in 91% yield. 
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Scheme 3.9 Deprotection of lactone 112 
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Scheme 3.10 Deprotection of lactone 122 
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Reagents and conditions: (a) 1:1 TFA:CH2Cl2, 1h 
 
 Following the deprotections to give the free acid 129, the lactone was 
coupled with N-methylthio lactam 73 using 1-ethyl-3-(3’-
dimethylaminopropyl)carbodiimide (EDCI) and a catalytic amount of N,N-
dimethylaminopyridine (DMAP) to give the lactam-lactone conjugate 130 in 36 % 
yield (Scheme 3.11).  
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Scheme 3.11 Coupling of acid 129 with N-thiolated β-lactam 73 
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 The coupling of the free acid 129 with N-sec-butylthio lactam 131 
(synthesized by Dr. Tyler Schertz in our lab) was accomplished using the same 
reaction conditions as for the coupling of the N-methylthio β-lactam 73, to give 
the desired product, 132, in 31% yield. The yields of these two coupling reactions 
represent un-optimized yields.  
 
Scheme 3.12 Coupling of acid 129 with N-thiolated β-lactam 131 
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The structures of 130 and 132 were confirmed by 1H NMR. The successful 
attachment of the lactams to the monomer can be seen by the shift in the 1H 
NMR spectrum of the two protons of the β-lactam ring. In the 1H NMR of 73, 
these two protons appear as a doublet of doublets at 5.3 and 5.2 ppm, and 
following the attachment to the acid 129, these two protons appear at 6.1 and 5.4 
ppm. In the 1H NMR spectrum of 131, these two protons appear as a multiplet at 
5.3 ppm, and following the attachment to 129, these two protons appear as a 
doublet of doublets at 6.1 and 5.4 ppm. 
 
3.2.4 Results of screening for anti-MRSA activity 
 
 The new lactam-lactone conjugates, 130 and 132, were screened for anti-
MRSA activity against the same nine strains of MRSA that were used to test the 
compounds shown in Chapters 1 and 2. The screening for bioactivity was 
accomplished using the Kirby-Bauer method of well diffusion as described in 
Chapter 2. The results of the testing are shown in Table 3.1. Also included for 
comparison are the two commercial drugs, penicillin G (Pen) and vancomycin 
(Van), as well as the β-lactams 73 and 131. 
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Table 3.1 Zones of growth inhibition for lactams and lactam-lactone 
conjugates against MRSA 
 
Pen
Van
73
131
130
132
8
16
19
32
15
23
16
15
17
28
17
21
10
16
17
29
15
22
14
16
19
28
15
21
12
21
18
28
14
22
12
15
16
25
16
21
19
15
19
29
16
21
15
15
18
29
16
21
nd
nd
18
30
14
22
MRSA
652
MRSA
653
MRSA
654
MRSA
655
MRSA
656
MRSA
657
MRSA
658
MRSA
659
MRSA
919
Cmpd
#
The values indicate the diameters in mm for the zone of growth inhibition after 24 h of incubation at 37 oC. 
Twenty micrograms of each test compound in DMSO solution was used. All of the microbes listed are β−
lactamase producing, methicillin-resistant strains of Staphylococcus aureus (MRSA). Those labelled as MRSA 
652-659 were obtained from a clinical testing laboratory at Lakeland Regional Medical Center, Lakeland, FL. 
MRSA 919 is ATCC 43300 and was purchased from American Type Culture Collections. Error values are within 
+/-1 mm. Penicillin G (Pen) and Vancomycin (Van) are included for reference. (nd, not determined).  
 
 The zones of inhibition obtained for all of the compounds in this study 
were around the same, or higher than, the commercial drugs penicillin G and 
vancomycin. In both cases, the activity of the β-lactams appears to be less for 
the lactam-lactone conjugates than for the parent C3 hydroxy β-lactams, 
however, this difference may be due to the molecular weight differences. As was 
seen in the previous SAR study of the N-organothio β-lactams (discussed in 
Chapter 1), the N-methylthio β-lactams (73 and 130) showed lower anti-MRSA 
activities than the N-sec-butylthio β-lactams (131 and 132).  The most significant 
thing to note from these results is that the anti-MRSA activity of the β-lactams is 
still retained after attachment to the functionalized lactone.  
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3.2.5 Results of screening for anti-Bacillus activity 
 
The new lactam-lactone conjugates, 130 and 132, were screened for anti-
Bacillus activity against the same seven Bacillus microbes that were used to test 
the compounds shown in Chapters 1 and 2. The screening for bioactivity was 
accomplished using the Kirby-Bauer method of well diffusion as described in 
Chapter 2. The results of the testing are shown in Table 3.2. Also included for 
comparison are the commercial drug, ciprofloxacin (Cip), as well as the β-lactams 
73 and 131.  
 
 
Table 3.2 Zones of growth inhibition for lactams and lactam-lactone 
conjugates against Bacillus 
 
Cip
73
131
130
132
B.
anthracis
Cmpd B.
globigii
B.
thuringensis
B.
megaterium
B.
coagulans
B.
subtilis
B.
cereus
39
24
25
17
22
33
14
26
15
23
40
19
19
14
17
41
17
24
15
19
42
17
24
15
20
41
11
26
13
22
33
19
19
17
18
Twenty micrograms of test compound in DMSO solution was used in each case. The values indicate the diameters 
in mm for the zone of growth inhibition obtained for each compound after 24 h of incubation at 37 oC. Error values 
are within +/- 1mm. Ciprofloxacin (Cip) is included as a reference. (nd, not determined).  
 
 As was the case with the anti-MRSA testing, the N-sec-butylthio β-lactams 
(131 and 132) showed larger zones of inhibition than the N-methylthio β-lactams 
(73 and 130). Similar to the results of the SAR studies discussed in Chapters 1 
and 2, none of the analogues prepared in this study had bioactivities that 
surpassed ciprofloxacin. The most significant thing to note from these results is 
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that the anti-Bacillus activity of the β-lactams is retained after attachment to the 
functionalized lactone.  
 
3.3 Conclusions 
 
 Lactones bearing a pendant benzyl ester substituent 108 and a pendant 
tert-butyl ester substituent 122 were both successfully synthesized in five and 
four steps respectively from commercially available starting materials. Both of 
these new lactones were easily deprotected to give the corresponding lactone 
bearing a pendant free carboxylic acid 129. The acid 129 was successfully 
coupled with both the C3 hydroxy N-methylthio β-lactam 73 and C3 hydroxy N-
sec-butylthio β-lactam 131. As was observed previously, the N-sec-butylthio 
derivatives exhibited greater bioactivities than the N-methylthio deriviatives. 
When molecular weight differences are taken into account, the bioactivity of the 
β-lactams does not diminish by the attachment to the lactone. Since 
incorporation of the N-thiolated β-lactams onto the caprolactone ring does not 
adversely affect the bioactivity of the lactams, it is hoped that attachment to the 
functionalized poly(ε-caprolactone) will also not have a detrimental affect on the 
bioactivity. The efforts towards synthesizing a N-thiolated β-lactam containing 
poly(ε-caprolactone) are discussed in chapter 4. 
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3.4 Experimental 
 
All reagents and solvents were purchased from Sigma-Aldrich Company or 
Fisher Scientific and used without further purification unless otherwise stated.  
Products were purified by flash column chromatography with J. T. Baker flash 
chromatography silica gel (200-400 mesh). NMR spectra were recorded in 
CDCl3. 13C NMR spectra were proton decoupled. 
 
Synthesis of phosphonium salt 114: Triphenylphosphine (23.6 g, 90.2 mmol) was 
dissolved in 100 mL of benzene and ethyl bromoacetate (15.06 g, 90.2 mmol) 
was added. The solution allowed to stir overnight at room temperature. The 
phosphium salt was isolated by filtration and washed with benzene to remove the 
residual triphenylphosphine. 1H NMR (250 MHz): δ 7.88-7.85 (6H, m), 7.75-7.70 
(3H, m), 7.67-7.64 (6H, m), 7.32-7.24 (2H, m), 5.58-5.53 (2H m), 4.00 (2H, m), 
1.04-1.02 (3H, m). 
 
Synthesis of ylide 115: Phosphonium salt 114 was dissolved in 100 mL of 20% 
sodium hydroxide in water and allowed to stir for 5 hours. The solution was 
extracted three times with 50 mL of benzene. The combined benzene layers 
were dried over Na2SO4 and the solvent was removed under reduced pressure to 
give 30.5 g (97%) or ylide 115 as a white solid. 1H NMR (250 MHz): δ 7.67-7.24 
(15H, m), 5.18 (1H, br s), 3.94 (2H m), 2.82, 1.30-1.05 (3H, m). 
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Synthesis of 116: Commercially available ketone 111 (5.0g, 32.0 mmol) was 
dissolved in 100 mL of benzene and ylide 115 (2 eq., 22.3g, 64.0 mmol) was 
added. The reaction was refluxed for 24 hours, the solvent was removed under 
reduced pressure, and the crude product was purified by flash column 
chromatography using 9:1 hexanes to ethyl acetate as the eluent to give 6.77 g 
(94%) of 116 as a colorless liquid. 1H NMR (250 MHz): δ 5.57 (1H, s), 4.08 (2H, 
q), 2.92 (2H m), 2.28 (2H, m), 1.19 (3H, t). 
 
Synthesis of 117: Alkene 116 (6.0g, 26.7 mmol) was dissolved in 40 mL of ethyl 
acetate. A catalytic amount of 10% Pd/C was added, and the mixture was 
shaken under 60 psi of hydrogen gas (Parr hydrogenator) for 24 h. The palladium 
was removed by filtration through celite, and the solvent was removed under 
reduced pressure to give 5.89g (98 %) of alkane 117 as a clear, colorless, liquid. 
1H NMR (250 MHz): δ 3.76 (2H, q), 3.58 (4H, s), 1.82 (2H, d), 2.28 (2H, m), 1.39-
1.31 (5H, m), 1.28-1.19 (4H, m), 0.89 (3H, t). 
 
Synthesis of 118: Ester 117 (5.2g, 22.9 mmol) was dissolved in 100 mL of 2% 
H2SO4 and allowed to stir at room temperature for 5 days (until the TLC showed 
that the reaction was no longer progressing). The acid was isolated by extracting 
five times with 50 mL of diethyl ether. The combined ether layers were washed 
with brine, dried over Na2SO4 and the solvent was removed by evaporating under 
reduced to pressure to give 2.83 g (81 %) of 118. 
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Synthesis of 119: Acid 118 (2.83 g, 18.1 mmol) was dissolved in 100 mL of 
acetonitrile. K2CO3 (3 eq. 7.50g, 54.3 mmol) and benzyl bromide (1.1 eq. 3.42 g, 
19.9 mmol) were added. The reaction was refluxed overnight, and then the base 
was removed by filtration and the solvent was removed by evaporating under 
reduced pressure. The crude product was purified by flash column 
chromatography using first 9:1 and then 4:1 hexanes to ethyl acetate as the 
eluent to give 3.9 g (88 %) of 119 as a colorless liquid. . 1H NMR (250 MHz): δ 
7.3-7.2 (5 H, m), 5.2 (2H, s), 2.44-2.25 (7H, m), 2.19-2.08 (2H m), 1.52-1.38(2H, 
m). 
 
Synthesis of 112: Ketone 119 (3.95g, 16.0 mmol) and mCBPA (1.5 eq. 4.16 g, 
24.1 mmol) were dissolved in chloroform and the reaction was refluxed for 5 
hours (until the TLC showed complete consumption of the starting material). The 
chloroform was removed under reduced pressure, and 150 mL of 5% NaHCO3 
solution was added to neutralize the reaction. The 5% NaHCO3 solution was then 
extracted three times with 100 mL of CH2Cl2. the combined CH2Cl2 layers were 
washed with 5 % NaHCO3, brine, dried over Na2SO4 and the solvent was 
removed under reduced pressure. The crude product was purified by flash 
column chromatography to give 3.24 g (77%) of lactone 112 as a colorless soft 
solid, m.p. 59-60 oC. 1H NMR (250 MHz): δ 7.35-7.20 (5 H, m), 5.08 (2H, s), 
4.38-4.05 (2H, m), 2.71-2.58 (2H m), 2.23-2.21 (2H, d), 2.19-2.01 (2H, m) 1.92-
1.18 (5H, m). 13C (63 MHz): δ 175.2, 171.3, 135.3, 128.2, 127.9, 127.8, 77.5, 
77.0, 76.5, 67.2, 65.9, 40.3, 36.4, 34.5, 32.5, 28.1. 
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Synthesis of 120: Ester 117 (6.0 g, 26.5 mmol) was dissolved in 50 mL of 
methanol and lithium hydroxide (3 eq., 3.33 g, 79.4 mmol) was added. The 
mixture was stirred at room temperature until the TLC showed complete 
conversion to the carboxylate. The reaction mixture was neutralized with 1M HCl 
and extracted five times with 60 mL of diethyl ether. The combined ether layers 
were dried over Na2SO4 and the solvent was removed under reduced pressure to 
give the 4.80 g (90 %) of free acid, 120. 
 
Synthesis of 121: Acid 120 (1.54 g, 7.7 mmol) dissolved in 100 mL of acetonitrile 
and potassium carbonate (3 eq., 3.19 g, 23.1 mmol) was added, followed by 
benzyl bromide (1.1 eq., 1.45 g, 8.47 mmol). The mixture was refluxed overnight. 
The base was removed by filtration and the solvent was removed under reduced 
pressure. The crude product was taken directly to the next step without further 
purification. 1H NMR (250 MHz): δ 7.28-7.22 (5H, m), 5.04 (2H, s), 3.76 (4H, S), 
2.19 (2H, d), 1.76-1.57 (5H, m), 1.62-1.42 (2H, m), 1.30-1.10 (2H, m). 
 
Compound 122: colorless crystals, m.p. 82-83 oC, 83 % yield.13C NMR (63 MHz): 
δ 175. 6, 171.3, 80.8, 67.8, 42.0, 37.1, 35.0, 33.0, 28.6, 28.1 
 
Compound 126: colorless liquid, 81 % yield1H NMR (250 MHz): δ 5.55 (1H, s), 
3.84 (4H, s), 2.88-2.82 (2H, m), 2.30-2.22 (2H, m), 1.78-1.64 (4H, m), 1.4 (9H, s); 
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13C NMR (63 MHz): δ 166.0, 158.5, 115.9, 108.0, 79.6, 64.4, 35.7, 34.9, 34.5, 
28.2, 26.7. 
 
Compound 127: colorless liquid, 57 % yield. 1H NMR (250 MHz): δ 3.69 (4H, s), 
1.90-1.85 (2H, d), 1.60-1.40 (5H, m), 1.40-0.90 (4H, m), 1.13 (9H, s); 13C NMR 
(63 MHz): δ 172.2, 108.5, 79.9, 64.1, 42.1, 34.1, 33.5, 29.8, 28.1. 
 
Compound 128: Acetal 127 (0.227 g, 0.89 mmol) was dissolved in 3.5 mL of 
reagent grade acetone (<0.4% water). Then iodine (0.1 eq. 0.11 g, 0.089 mmol) 
was added. The reaction was stirred at room temperature for 1 hour, with 
constant monitoring by TLC. The reaction was stopped when no further change 
was seen by TLC. The acetone was removed by evaporation, the residue was 
dissolved in 10 mL of CH2Cl2, and washed with 5 mL of 5% Na2S2O3; 10 mL of 
water, and 10 mL of brine. The CH2Cl2 layers were dried over sodium sulfate and 
the solvent was removed under reduced pressure. The crude product was 
purified by flash column chromatography using 9:1 hexanes to ethyl acetate as 
the eluent to give 0.093 g (49%) of 128 as a colorless solid, m.p. 36-38 oC. 1H 
NMR (250 MHz): δ 2.35-2.21 (4H, m), 2.15-2.04 (4H, m), 1.82-2.00 (2H, m), 1.28 
(9H, s); 13C NMR (63 MHz): δ 211.0, 171.6, 80.3, 41.3, 40.5, 33.1, 32.2, 28.0. 
 
Synthesis of 130: Acid 129 (0.025 g, 0.145 mmol), lactam 73 (0.038 g, 0.145 
mmol), EDCI (1.2 eq., 0.033 g, 0.174 mmol) and a catalytic amount of DMAP 
were all dissolved in 2 mL of freshly distilled CH2Cl2, and stirred overnight at 
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room temperature. The EDCI was removed by washed with water. The CH2Cl2 
was dried over sodium sulfate and the solvent was removed by evaporation. The 
crude product was purified by flash column chromatography using 4:1 
hexanes:ethyl acetate as the eluent to give 0.0223 g (36%) of 130. 1H NMR (250 
MHz): δ 7.37-7.18 (5H, m), 6.08-6.02 (2H, m), 5.46-5.39 (2H, m), 4.32-4.19 (1H, 
m), 4.12-3.97 (1H, m), 2.45 (3H, s), 2.2-1.1(12H, m); 13C NMR (63 MHz): δ 
170.3, 168.2, 134.4, 130.6, 130.2, 130.0, 129.8, 128.8, 126.8, 126.8, 68.3, 68.1, 
62.2, 36.1, 36.0, 30.5, 30.4, 30.3, 28.4, 28.3, 21.9. 
 
Compound 132: 31% yield. 1H NMR (250 MHz): δ 7.5-7.1 (5H, m), 6.2-6.0 (1H, 
m), 5.5-5.4 (1H, m), 4.4-4.2 (1H, m), 4.2-4.0 (1H, m), 3.1-2.9 (1H, m), 2.4-1.5 
(10H, m), 1.3-1.1 (5H, m), 1.0-0.9 (3H, m).  
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Chapter 4 
Functionalized Caprolactone Cooligomers: Cooligomerization, Attachment 
of N-Thiolated β-Lactams and Biological Evaluation 
 
4.1 Introduction 
 
4.1.1 Poly(ε-caprolactone) 
 
 There has been significant research in the past two decades on the use of 
synthetic polyesters for biomedical purposes such as applications in surgery and 
medicine. Aliphatic polyesters such as poly(lactic acid) (PLA), poly(glycolic acid) 
(PGA) and poly(ε-caprolactone) (PCL) are often used as biomaterials due to their 
low toxicity, good biocompatibility, and excellent mechanical properties.1 Recent 
work in our laboratory has focused on the attachment of our N-thiolated β-lactam 
antibiotics to polymers to form new biomaterials.2 This study focuses on 
covalently binding our lactams to a poly(ε-caprolactone) backbone formed from 
the cooligomerization of ε-caprolactone with the new substituted lactones, 112 
and 122, that were described in Chapter 3. 
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4.1.2 Polymerization of ε-caprolactone 
 
Poly(ε-caprolactone) is formed from the ring-opening polymerization 
(ROP) of the ε-caprolactone monomer 133 (Figure 4.1). 
 
Figure 4.1 Ring-opening polymerization of ε-caprolactone 133 
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There are many catalysts that can be used for this polymerization, but the most 
commonly used catalyst is tin 2-ethylhexanoate (134) (Figure 4.2), commonly 
known as stannous octoate [Sn(Oct)2]. Stannous octoate is used most often 
because it is inexpensive, non-toxic and highly efficient.3 It is considered safe for 
use in the making of polymers for biomedical applications because it is already 
approved by the Food and Drug Administration (FDA) as a food additive.4 
 
Figure 4.2 Structure of Sn(Oct)2 
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Stannous octoate acts as a catalyst for the polymerization reaction, and it 
is used in conjunction with an active hydrogen compound (either purposely 
added or as an impurity). The actual polymerization mechanism has been much 
debated3, however, reports in recent years favor the mechanism shown in Figure 
4.3.3 The first three steps, A, B, and C, represent initiation steps, D and E are 
propogation steps, and F is a termination step. In the first step (A) of the 
mechanism, stannous octoate reacts with an active hydrogen compound to form 
a stannous alkoxide species (135), thereby liberating a molecule of 2-
ethylhexanoic acid (136). Next, in the second step of the mechanism, 135 reacts 
either with another equivalent of alcohol to produce the stannous dialkoxide 
initiator (137) (shown in step B), or with an equivalent of water to a stannous 
alcohol derivative (138) (shown in step C). Of these two possible pathways, the 
desired pathway is B, leading to the formation of the stannous dialkoxide 137, 
because 137 is a much more efficient initiator than 138. The reaction of 138 with 
a lactone monomer proceeds via a coordination-insertion mechanism shown in 
step D to generate the first actively propagating chain end, 139. This chain can 
then react with another molecule of the lactone to build onto the chain as shown 
in step E. The chain termination step is shown in step F, where 140 can then can 
then undergo a rapid exchange of the stannous alkoxide monomer for a proton 
from any hydroxyl compound present (alcohol, water, chain end). Evidence that 
supports this mechanism includes the observation that the rate of ROP can be 
increased by the addition of butanol to distilled Sn(Oct)2,5 and also the direct 
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observation (by MALDI-TOF) of tin covalently bound to the end of the polyester 
chain.6 
 
Figure 4.3 Likely mechanism for the Sn(Oct)2 catalyzed polymerization of  
ε-caprolactone3 
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 There are possible side reactions that can take place during these 
polymerization reactions that can lead to lower molecular weight polymers, and 
broader molecular weight distributions. An intermolecular transesterification 
reaction, such as the one shown in Figure 4.4, is one type of side reaction that 
can occur. 
  
 
Figure 4.4 Intermolecular transesterification 
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 Another type of side reaction that can take place is an intramolecular 
transesterification reaction that leads to the formation of cyclic oligomers (Figure 
4.5). This is known as polymer back-biting. The possibility of inter- and 
intramolecular transesterification reactions increases with higher reaction 
temperatures and longer reaction times.7 
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Figure 4.5 Intramolecular transesterification (back-biting) 
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4.1.3 Examples of copolymerization of ε-caprolactone with substituted 
lactones from the literature 
 
 In recent years, there have been reports on the copolymerization of ε-
caprolactone with caprolactones that contain functional groups.  Detrembleur et 
al. reported the copolymerization of ε-caprolactone with 5-bromocaprolactone 
(103) (Scheme 4.1).8 
 
Scheme 4.1 Copolymerization of ε-caprolactone with 5-bromocaprolactone 
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 These copolymerization reactions were carried out in toluene solution at  
0 oC using aluminum triisopropoxide [Al(OiPr)3] as the catalyst. Copolymers (142) 
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of the substituted lactone 133 and the unsubstituted ε-caprolactone 103 were 
formed successfully in varying ratios with narrow molecular weight distributions. 
When the content of the substituted lactone 133 was increased beyond 30  
mol %, the copolymers were found to exist as viscous liquids. 
Trollsås et al. reported the copolymerization of ε-caprolactone 103 with 
lactones that bore pendant ester functionalities (Scheme 4.2).9 
 
Scheme 4.2 Copolymerization of ε-caprolactone with substituted lactones 
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 These copolymerizations were performed in bulk (solventless) at 110 oC 
using Sn(Oct)2 as the catalyst and an alcohol as a initiator. Previously, the same 
group had reported the observation that substituted lactones generally react 
slower under these polymerization conditions than unsubstituted ε-caprolactone 
133.10 In this study, they found that monomers 106 and 107 were particularly 
slow to react, and that the molecular weights that they obtained were lower than 
what was expected. For the homopolymerization of the benzyl ester 106, the 
molecular weights obtained (from size exclusion chromatography, SEC) were 
1000 for the reaction using Al(OiPr)3, and 2000 for the reaction using Sn(Oct)2. 
For the homopolymerization of the tert-butyl ester 107, a molecular weight of 
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2000 was obtained for the polymerization catalyzed by Al(OiPr)3. For the 
copolymerization of 20% 107 and 80 % ε-caprolactone 133, a molecular weight 
of 13000 (by SEC) was obtained. They observed that the copolymerization of ε-
caprolactone with the benzyl ester 106 was not as successful and gave lower 
than expected molecular weights (the exact value was not stated for this system).  
 The copolymerization of ε-caprolactone with RS-β-benzyl malolactonate 
(145) (Scheme 4.8) was recently reported by He.11 This copolymerization 
reaction was studied using Sn(Oct)2 as the catalyst. The temperatures, 
concentration of the catalyst and monomer ratios were varied. 
 
Scheme 4.3 Copolymerization of ε-caprolactone with RS-β-benzyl 
malolactonate 
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This reaction failed at 90 oC, but was successful at 110, 130, 150 and 170 oC. 
The reaction temperature that was found to give the highest yields and the 
highest molecular weights was 130 oC. The content of RS-β-benzyl 
malolactonate, 145, in the copolymers was observed to be much lower than what 
was expected, and the molecular weight of the copolymers 146 decreased as the 
amount of 145 increased, indicating that 145 reacts much slower than ε-
caprolactone 133. Changing the concentration of the catalyst was not found to 
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have an effect on the molecular weight of the copolymers. All of the copolymers 
that were formed in the study were found to be liquids at temperatures above 50 
oC, and the copolymers that contained more than 16.2 % of 145 were found to be 
liquids at room temperature. 
 
4.2 Results and Discussion 
 
4.2.1 Cooligomerizations of benzyl ester containing lactone 112 with ε-
caprolactone 
 
 
 The lactone bearing a pendant benzyl ester, 112, whose synthesis was 
described in Chapter 3, was cooligomerized with ε-caprolactone (Scheme 4.4). 
The reactions were carried out in bulk at 130 oC using Sn(Oct)2 as the catalyst, 
following the procedure of He.11 
 
Scheme 4.4 Cooligomerization of lactone 112 with ε-caprolactone 
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The cooligomerization was attempted with 10, 15, 20, 25, 30, and 100 mol % of 
lactone 112 with a 1/1000 (molar ratio) of the catalyst Sn(Oct)2. The 
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cooligomerizations using 10, 15, and 20 mol % of 112 were successful. The 
yields of the copolymerization reactions were extremely low using 25 and 30 mol 
% of 112, and the products were liquids. Attempted isolation of the products from 
these two reactions was unsuccessful. The attempted homopolymerization of 
112 was unsuccessful. This was not surprising considering that Trollsås had 
reported for similar monomers (106 and 107) that homopolymerization did not 
occur to any appreciable extent.9 
 
Table 4.1 Cooligomers 147 
Entry 112 Content
Feed   Oligomerb
Time MWa
A
B
C
10%
20%
30%
7.6%
13.9%
17.9%
24h
48h
48h
~1000
~1000
~1000
a Molecular weights shown represent a crude estimate 
from the MALDI spectrum b from 1H NMR analysis  
 
The proportion of the lactone 112 in the cooligomers was 7.6, 13.8, and 17.9 %, 
slightly lower in than in the feeding dose (Table 4.1). The molecular weights of 
the cooligomers were also low. The substituted monomer, 112, is a low-melting 
waxy solid that is very difficult to remove water from. It is likely that the presence 
of water impurities lowers the molecular weights of the oligomers by forming a 
less active initiating species (138, Figure 4.3). Having a less active initiating 
species could potentially slow the rate of the oligomerization and increase the 
likelihood of competing transesterification reactions (Figures 4.4 and 4.5), which 
would result in lower molecular weight oligomers. It is also possible that the 
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Sn(Oct)2 is also coordinating with the carbonyl of the pendant benzyl ester group 
instead of the carbonyl of the lactone ring. A positive result from these 
experiments was that examination of the MALDI-TOF spectra of the oligomers 
did confirm the incorporation of lactone 112 into the cooligomers 147 (Figure 
4.6). This can be seen by the loss of 262 (the MW of benzyl ester containing 
lactone 112) and the loss of 114 (MW of ε-caprolactone 133) associated with the 
same set of peaks in the MALDI spectrum. Although the molecular weight of 
these oligomers was lower than what was hoped for, this still provided a new 
material to study the attachment of the N-thiolated β-lactams. This new material 
could then be checked for anti-MRSA and anti-Bacillus properties.  
 
Figure 4.6 MALDI spectrum of cooligomer 147 
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4.2.2 Cooligomerizations of tert-butyl ester containing lactone 122 with ε-
caprolactone 
 
 
 The lactone bearing a pendant tert-butyl ester, 122, described in Chapter 
3, was cooligomerized with ε-caprolactone 133 (Scheme 4.5). The reactions 
were carried out in bulk, at 130 oC, using Sn(Oct)2 as the catalyst. 
 
 
Scheme 4.5 Cooligomerization of lactone 122 with ε-caprolactone 
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 The cooligomerization was attempted with 10, 15, and 20 mol % of lactone 
122 with a 1/1000 (molar ratio) of the catalyst Sn(Oct)2, and a 1/40 (molar ratio) 
of methanol was added as an active hydrogen compound. The tert-butyl ester 
containing monomer 122 was a much more crystalline monomer than the benzyl 
ester containing monomer 112, and it was hoped that this property would lead to 
less water impurities in the reaction, and thus lead to higher molecular weight 
cooligomers (148). The proportion of the lactone 122 found to be incorporated 
into the oligomers was 10, 11 and 16% (Table 4.2). 
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Table 4.2 Oligomers 148 
Entry 122 Content
Feed   Oligomerb
Time MWa
A
B
C
10%
20%
30%
10%
11%
16%
24h
48h
48h
~1000
~1000
nd
a Molecular weights shown represent a crude estimate from the MALDI 
spectrum after deprotection of the tbutyl ester b from 1H NMR analysis. 
(nd, not determined)  
 
 All attempts to analyze these oligomers 148 via MALDI-TOF failed at this stage. 
However, the oligomers could be analyzed by MALDI-TOF following the cleavage 
of the tert-butyl ester group (Section 4.2.3, Scheme 4.7). 
 
4.2.3 Deprotection of the oligomers 
 
 The deprotection of the oligomers containing the benzyl ester was 
accomplished by hydrogenolysis (Scheme 4.6).  
 
Scheme 4.6 Deprotection of the benzyl ester containing oligomer 147 
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 The hydrogenolysis of the oligomer was carried out in hydrogen 
atmosphere (under a hydrogen-filled balloon) using 10% Pd/C as the catalyst, 
and ethyl acetate as the solvent. Ethyl acetate was selected for the solvent 
because it was capable of dissolving the oligomers both before and after the 
oligomerization. The reaction was complete after stirring overnight under 
hydrogen atmosphere to give 149 in nearly quantitative yield. The 1H NMR of the 
hydrogenolyzed product showed the complete disappearance of the peaks 
associated with the benzyl group (at 5.2 and 7.3 ppm). The MALDI spectrum of 
the hydrogenolyzed product showed the loss of 172 amu, which corresponds to 
the weight of the substituted monomer after the ester protecting group is cleaved.  
 The deprotection of the oligomers containing the tert-butyl ester was 
accomplished using trifluoroacetic acid (TFA) to give carboxylic acid  149 
(Scheme 4.7).  
 
Scheme 4.7 Deprotection of the tert-butyl ester containing oligomer 148 
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 The deprotection of the tert-butyl group was accomplished using a solution 
of 50% TFA in methylene chloride. The reaction was complete to give 
deprotected oligomers 149 in quantitative yield after 1 hour of stirring at room 
temperature. The removal of the tert-butyl ester was confirmed by 1H NMR by the 
disappearance of the singlet associated with the tert-butyl group (1.4 ppm). 
Following the deprotection of the tert-butyl ester groups to give 149, the MALDI-
TOF analysis of the oligomers was attempted again. This time, a spectrum was 
obtained for these oligomers. Unfortunately, the molecular weight of these 
oligomers was again low (~1000). However, the MALDI spectrum showed the 
loss of 172 amu from the chain, confirming that the substituted lactone had been 
incorporated into the oligomer chain. As was the case with the oligomers 147 
(formed from the benzyl ester bearing lactone 112)  the molecular weights of the 
oligomers formed from the tert-butyl ester containing lactone 122 were less than 
what was desired; however, a new, functionalized oligomer that could be used to 
test the attachment of our N-thiolated β-lactams was obtained.  
 
4.2.4 Attachment of N-thiolated β-lactams 73 and 131 to the oligomer 
 
 The attachment of the N-thiolated β-lactams to the oligomer 149 that 
contained a pendant carboxylic acid group was accomplished using the same 
method described previously (in Chapter 3) for the attachment of the N-thiolated 
β-lactams to the lactone monomers (Scheme 4.8). 
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Scheme 4.8 Attachment of N-thiolated β-lactams to the carboxylic acid 
containing oligomer 149 
 
O
O
O
O
n
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O
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O
O
O
O
CO2H
n
O
O
N
O
SR
Cl
149 73   R=Me131 R=s-Bu
+
150 R=Me
151 R=s-Bu
a
Reagents and conditions: (a) 1.5 eq. EDCI, cat. DMAP, dry CH2Cl2,rt  
 
 The oligomers containing 7.6% of the carboxylic acid-substituted lactone 
were selected for this reaction. Coupling of the free acid containing oligomers to 
the N-thiolated β-lactams was accomplished using 1.5 equivalents of EDCI and a 
catalytic amount of DMAP in freshly distilled methylene chloride. The successful 
attachment of the β-lactams to the oligomer can be seen by the shift in the 1H 
NMR spectrum of the two protons of the β-lactam ring. In the 1H NMR of 73, 
these two protons appear as a doublet of doublets at 5.3 and 5.2 ppm, and 
following the attachment to the oligomer 149,  these two protons appear at 6.2 
and 5.5 ppm (Figure 4.7). 
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Figure 4.7 Expanded region 1H NMR spectra for β-lactam 73 and β-lactam 
bearing cooligomer 150 
b) Vicinal protons on the β-
lactam ring of 150
a) Vicinal protons on the β-
lactam ring of 73
 
In the 1H NMR of 131, these two protons appear as a multiplet at 5.3 ppm, 
following the attachment to the oligomer 149,  these two protons appear as a 
doublet of doublets at 6.1 and 5.4 ppm. An analogous shift had been observed 
previously for the coupling of hydroxy lactams 73 and 131 to lactone 129 to give 
esters 130 and 132. 
 
4.2.5 Results of screening for anti-MRSA and anti-Bacillus activity 
 
 The new N-thiolated β-lactam bearing oligomers 150 and 151 were 
screened for anti-MRSA activity against the same nine strains of MRSA that were 
used previously for testing the N-thiolated β-lactam analogues. The screening for 
 95
bioactivity was accomplished using the Kirby-Bauer method of disc diffusion as 
described in Chapter 2. The oligomers 150 and 151 were tested by disc diffusion 
rather than well diffusion because they were completely insoluble in the DMSO 
solvent that is used for well diffusion. The results of the anti-MRSA testing are 
shown in Table 4.3. Also included in the Table 4.3 are the zones of growth 
inhibition for the C3 hydroxy β-lactams 73 and 131, the lactam-lactone 
conjugates 130 and 132, and a control sample of the 7.6% oligomer 147. The 
control oligomer 147 was included to exclude the possibility that the oligomer 
itself (or any residual tin initiator) was inhibiting bacterial growth. 
 
Table 4.3 Zones of growth inhibition against MRSA 
73
131
130
132
150
151
147a
19
32
15
23
9
15
0
17
28
17
21
11
16
0
17
29
15
22
10
15
0
19
28
15
21
10
14
0
18
28
14
22
9
16
0
16
25
16
21
10
15
0
19
29
16
21
11
15
0
18
29
16
21
12
16
0
18
30
14
22
9
15
0
MRSA
652
MRSA
653
MRSA
654
MRSA
655
MRSA
656
MRSA
657
MRSA
658
MRSA
659
MRSA
919
Cmpd
#
The values indicate the diameters in mm for the zone of growth inhibition after 24 h of incubation at 37 oC. 
Twenty micrograms of each test compound applied to a cellulose disc as a chloroform solution was used. 
a 400 micrograms of the control copolymer was applied to the cellulose disc as a chlorform solution.
All of the microbes listed are β−lactamase producing, methicillin-resistant strains of Staphylococcus aureus 
(MRSA). Those labelled as MRSA 652-659 were obtained from a clinical testing laboratory at Lakeland 
Regional Medical Center, Lakeland, FL. MRSA 919 is ATCC 43300 and was purchased from American Type
Culture Collections. Error values are within +/-1 mm.  
 
All of the compounds which contained the N-sec-butylthio β-lactams (131,132 
and 151) showed larger zones of growth inhibition than the compounds which 
contained the N-methylthio β-lactams (73, 130, and 151). This trend is consistent 
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with what was observed during the N-thiolated β-lactam SAR study (Chapter 2). 
In each series of compounds, the N-sec-butylthio β-lactam containing 
compounds and the N-methylthio β-lactam containing compounds, the β-lactams 
(73 and 131) had greater anti-MRSA activity than the lactam-lactone conjugates 
(130 and 132), which had greater activity than the lactams attached to the 
cooligomers (150 and 151) (Figure 4.8) This difference in activity may be due to 
molecular weight differences and uncertainty of the loading efficiency of the β-
lactams onto the oligomers. The most important thing to note from these results 
is the two oligomers (150 and 151) that have N-thiolated β-lactams covalently 
bound to the oligomer backbone possess anti-MRSA activity, and that covalent 
bonding of the β-lactams to an oligoester backbone does not interfere with the 
bioactivity! The control oligomer, 147, showed no zones of growth inhibition in 
this assay, which confirms that the bioactivity of 150 and 151 is due to the 
attached β-lactams.  
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Figure 4.8 Kirby-Bauer disc diffusion test plate for compounds 131, 132, 
and 151 against MRSA 655 
NO
O
Cl
S
polymer
O
151
N
O
HO
S
Cl
131
NO
O
Cl
S
O
O
O
132
 
 The two new β-lactam bearing oligomers, 150 and 151, were also 
screened for anti-Bacillus activity against the same seven Bacillus microbes that 
were examined previously (Table 4.4). Also included in Table 4.4 for comparison 
are the zones of growth inhibition for the C3 hydroxy β-lactams 73 and 131 and 
the lactam-lactone conjugates 130 and 132.  
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Table 4.4 Zones of growth inhibition against Bacillus 
73
131
130
132
150
151
B.
anthracis
Cmpd B.
globigii
B.
thuringensis
B.
megaterium
B.
coagulans
B.
subtilis
B.
cereus
24
25
17
22
11
22
14
26
15
23
9
23
19
19
14
17
9
14
17
24
15
19
9
19
17
24
15
20
12
20
11
26
13
22
2
22
19
19
17
18
12
18
Twenty micrograms of test compound in DMSO solution was used in each case. The values indicate the diameters 
in mm for the zone of growth inhibition obtained for each compound after 24 h of incubation at 37 oC. Error values 
are within +/- 1mm. (nd, not determined).  
 
 The trend in the bioactivity of these compounds against Bacillus exactly 
parallels what was seen for MRSA, with the N-sec-butylthio β-lactam containing 
compounds (131, 132, and 151) having larger zones of growth inhibition than the 
N-methylthio β-lactam containing variants (73, 130, and 150). It is exciting to 
observe that the two β-lactam bearing cooligomers (150 and 151) show anti-
Bacillus activity, indicating that attachment of the lactams to the oligoester 
backbone did not preclude antibacterial activity of these compounds. From 
previous studies (described in Chapters 1 and 2), we know that the N-thiolated β-
lactam antibiotics act by entering the bacterial cell. Therefore, in order for these 
new oligomers to possess the same bioactivity, we must assume that the β-
lactams are entering the cells, however, at this point, we do not know whether or 
not the lactams are still attached to the oligomers when they do so.   
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4.3 Conclusions 
 
 In conclusion, both of the new functionalized caprolactone monomers (112 
and 122) that were described in Chapter 3 could be cooligomerized with ε-
caprolactone to form new, functionalized oligomers 147 and 148. While the 
molecular weights of these new oligomers were lower than desired, a new 
material with which to test the attachment of the N-thiolated β-lactams was 
obtained. The deprotection of both 147 and 148 was accomplished under mild 
conditions to give the oligomer 149 which bore a pendant free carboxylic acid 
group. An N-methylthio β-lactam 73, and an N-sec-butylthio β-lactam 131 were 
both successfully covalently attached to the oligoester backbone, and the 
resulting β-lactam bearing oligomers were screened for anti-MRSA and anti-
Bacillus activity. Both of the new drug-containing oligomers were found to inhibit 
the growth of the all nine MRSA and seven Bacillus strains that were tested. This 
provides the precedent needed for further experiments and to make use of the 
C3 position of the β-lactam ring to bind the antibiotic to a biodegradable 
oligoester as a means to retain the bioactivity of the lactam. 
 Thus far, the attachment of other antibiotics, such as 6-aminopenicillinic 
acid and ciprofloxacin has been unsuccessful. This is, however, an area which 
still needs to be explored in detail to determine what other drug molecules can be 
bound to these oligomers. We believe that they attachment of any drug 
molecules to the oligomers will need to be accomplished following the 
oligomerization reaction due to the Lewis acidity of the oligomerization catalyst. 
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 Based on previous studies of aliphatic polyesters, we believe that these 
new oligomers will also be biodegradable, but further studies will need to be 
performed to confirm this. Further experiments to try to increase the molecular 
weight of these oligomers should also be explored to increase the scope of 
potential applications of these new materials. Another alternative to this would be 
to graft the oligomers to a pre-formed polyester. 
 The experiments described within this dissertation represent the beginning 
point to an exciting new project that needs to be explored further. The successful 
attachment of the N-thiolated β-lactams to a biodegradable material opens up 
many new avenues for us to explore. We can envision many biomedical 
applications for these new materials such as antibacterially-active biodegradable 
sutures and coatings for implants. 
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4.4 Experimental 
 
ε-Caprolactone was dried over CaH, distilled under reduced pressure, and stored 
over activated 4Ǻ molecular sieves before use. Tin (II) ethylhexanoate was 
purchased from Aldrich and used as received. Toluene was dried over calcium 
hydride and distilled before use. Anhydrous methanol (<99.9%) was purchased 
from Acros and used as received. Monomers 112 and 122 were purified by flash 
column chromatography and dried in an Albderhalden drying apparatus overnight 
(P2O5, refluxing acetone). All other reagents were used as received. NMR 
spectra were recorded in CDCl3. 13C NMR spectra were proton decoupled. 
MALDI analysis was performed by Dr. Ted Gauthier in the USF Department of 
Chemistry Mass Spectrometry Facility, and conducted in positive ion mode using 
2,5-dihydroxybenzoic acid (DHB) as the matrix. 
  
Representative oligomerization procedure: Lactone 112 ( 0.200g, 0.763 mmol) 
was weighed into a vial and dried overnight using an Albderhalden drying 
apparatus. An oil bath was preheated to 130 oC. The Albderhalden drying 
apparatus was opened in a glove bag under a nitrogen atmosphere. Inside the 
glove bag, previously distilled ε-caprolactone (0.784g, 6.87 mmol) was added to 
the vial containing the substituted lactone. The vial was capped with a cap that 
contained a teflon septum and then removed from the glove bag, sealed with 
teflon tape and placed in the constant temperature oil bath at 130 oC. After 
allowing 20 minutes for the monomers to reach the temperature of the oil bath, 
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the Sn(Oct)2 initator was added via syringe.( 7.63 X 10-3mmol, 76.3 μL of a 0.1M 
solution in freshly distilled toluene). After 24 hours, the vial was removed from the 
oil bath. The residue was dissolved in a small amount of chloroform and 
precipitated from an ice-cold solution of 3:2 hexanes:diethyl ether. The solvent 
was removed from the precipitated cooligomer and then dried under vacuum 
overnight to give 0.47g (48 %) of the cooligomer.  
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Appendix 1 
 
Selected spectra 
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1H NMR spectrum for 63 
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1H NMR spectrum for 73 
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13C NMR spectrum for 73 
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1H NMR spectrum for 74 
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13C NMR spectrum for 74 
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1H NMR spectrum for 75 
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13C NMR spectrum for 75 
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1H NMR spectrum for 76 
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13C NMR spectrum for 76 
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1H NMR spectrum for 77 
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13C NMR spectrum for 77 
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1H NMR spectrum for 78 
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13C NMR spectrum for 78 
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1H NMR spectrum for 79 
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13C NMR spectrum for 79 
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1H NMR spectrum for 82 
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13C NMR spectrum for 82 
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1H NMR spectrum for 84 
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1H NMR spectrum  for 85 
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1H NMR spectrum for 87 
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13C NMR spectrum for 87 
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1H NMR spectrum for 88 
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13C NMR spectrum for 88 
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1H NMR spectrum for 89 
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13C NMR spectrum for 89 
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1H NMR spectrum for 90 
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13C NMR spectrum for 90 
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1H NMR spectrum for 91 
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13C NMR spectrum for 91 
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1H NMR spectrum for 92 
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1H NMR spectrum for 93 
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13C NMR spectrum for 94 
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1H NMR spectrum for 95 
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13C NMR spectrum for 95 
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1H NMR spectrum for 96 
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13C NMR spectrum for 96 
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1H NMR spectrum for 97 
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13C NMR spectrum for 97 
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1H NMR spectrum for 98 
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13C NMR spectrum for 98 
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1H NMR spectrum for 99 
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13C NMR spectrum for 99 
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1H NMR spectrum for 112 
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13C NMR spectrum for 112 
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1H NMR spectrum for 114 
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1H NMR spectrum for 115 
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1H NMR spectrum for 116 
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1H NMR spectrum for 117 
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1H NMR spectrum for 118 
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1H NMR spectrum for 119 
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1H NMR spectrum for 121 
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1H NMR spectrum for 122 
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13C NMR spectrum for 122 
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1H NMR spectrum for 126 
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13C NMR spectrum for 126 
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1H NMR spectrum for 127 
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13C NMR spectrum for 127 
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1H NMR spectrum for 128 
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13C NMR spectrum for 128 
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1H NMR spectrum for 129 
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1H NMR spectrum for 130 
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13C NMR spectrum for 130 
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1H NMR spectrum for 131 
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1H NMR spectrum for 132 
 
 
 
 
 
 169
1H NMR spectrum for 147A 
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1H NMR spectrum for 147B 
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1H NMR spectrum for 147C 
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1H NMR spectrum for 148A 
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13C NMR spectrum for 148A 
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1H NMR spectrum for 148B 
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1H NMR spectrum for 148C 
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1H NMR spectrum for 149 
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13C NMR spectrum for 149 
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1H NMR spectrum for 150 
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1H NMR spectrum for 151 
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MALDI spectrum for 147a after debenzylation 
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MALDI spectrum for 147a after debenzylation (expanded region) 
 
 
 
 
 182
MALDI spectrum for 184a after deprotection 
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MALDI spectrum for 184a after deprotection (expanded region) 
 
  
 
 
 
 184
MALDI spectrum for 148b after deprotection 
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MALDI spectrum for 148b after deprotection (expanded region) 
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